The British Journal of Psychiatry

INDEX TO VOLUME 174

JANUARY–JUNE
1999

© The Royal College of Psychiatrists

CENTRE FOR POLICY ON AGEING
25-31 IRONMONGER ROW
LONDON EC1V 3QP
Telephone 01 253 1787

ISSN 0007-1250

Index to Volume 174

Compiled by Linda English

PART I — SUBJECTS 3–16

PART II — CONTRIBUTORS 16–23

PART III — BOOK REVIEWS 23–24

Abbreviations: C, correspondence; suppl., supplement

PART I. SUBJECTS

Abnormal Involuntary Movement Scale
Tardive dyskinesia in patients with schizophrenia during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30

Abreaction techniques
Misuse. Unreliable admissions to homicide. Gisli H. Gudjonsson *et al* 455–459

Acute brief psychosis
And fever, in urban and rural settings in north India. Pamela Y. Collins *et al* 520–524

Admission data
Mental health among Irish people living in Britain. D. Walsh (C) 79–80. P. Bracken *et al* (*Authors' reply*) (C) 80

Adolescence
Difficulties in family functioning and anorexia nervosa. Simon Gowers and Clive North 63–66
Neurodevelopmental antecedents of early-onset bipolar affective disorder. Engilbert Sigurdsson *et al* 121–127
Neurodevelopmental delay in the severely ill. P. McConville and N. Walker (C) 563. E. Sigurdsson and E. Fombonne (*Authors' reply*) (C) 563–564
see also **Childhood and adolescence**

Adversity
Aetiological risk factors for personality disorders. Jeremy W. Coid 530–538
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
Psychosocial adversity and child psychopathology. Michael L. Rutter (*Review Article*) 480–493
Review of community prevalence of depression in later life. A. T. F. Beekman *et al* (*EURODEP Study*) 307–311

Affective disorders
Neurodevelopmental delay in the severely ill. P. McConville and N. Walker (C) 563. E. Sigurdsson and E. Fombonne (*Authors' reply*) (C) 563–564
see also **Bipolar affective disorder, Depression** *and* **Schizoaffective disorder**

Agoraphobia
With panic disorder. Moclobemide and cognitive–behavioural therapy. B. Loerch *et al* 205–212

Akathisia
Neuroleptic-induced. Treatment with the 5-HT_2 antagonist mianserin. M. Poyurovsky *et al* 238–242
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43

Alcohol misuse
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. K. E. Hayford *et al* 173–178
Prevalence of substance misuse in first-episode psychosis. Roch Cantwell *et al* 150–153

Alzheimer's disease
Economic impact in the UK. E. Souêtre *et al* 51–55
Natural history of behavioural changes and psychiatric symptoms. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
New drugs. Alistair Burns *et al* (*Editorial*) 476–479
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Amiodarone
Induced depression. A. Ambrose and E. Salib (C) 366–367

Amnesia
Misdiagnosis. Unreliable admissions to homicide. Gisli H. Gudjonsson *et al* 455–459

Amphetamine
Risperidone treatment of amphetamine psychosis. A. Jha and H. Fourie (C) 366

Analyses
Antipsychotic polypharmacy and early death. R. P. Snaith (C) 368. J. L. Waddington *et al* (*Authors' reply*) (C) 368–369
Cost-effectiveness of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Sarah Byford *et al* 56–62
Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in trials. Paola Bollini *et al* (*Review Article*) 297–303
Two-phase epidemiological surveys in psychiatric research. Graham Dunn *et al* (*Editorial*) 95–100

Anorexia nervosa
Adolescent. Difficulties in family functioning. Simon Gowers and Clive North 63–66
As a phenotype of cognitive impairment in schizophrenia. Y. Yamashita *et al* (C) 558

Anticholinergics
Cholinergic aspects of schizophrenia. Rajiv Tandon (suppl. 37) 7–11
Orphenadrine. Lars Slørdal and Pål Gjerden (C) 275–276

Antidepressants
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25
Effectiveness. Meta-analysis of dose–effect relationships in trials. Paola Bollini *et al* (*Review Article*) 297–303

Medication for depression following the acute episode. Rajini Ramana *et al* 128–134
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265
see also individual names

Antiepileptics
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265

Antipsychotics
An approach to treatment resistance in schizophrenia. Stephen R. Marder (suppl. 37) 19–22
Cholinergic aspects of schizophrenia. Rajiv Tandon (suppl. 37) 7–11
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
New antipsychotics –preclinical and clinical comparisons. R. Kerwin (ed.) (suppl. 38) 1–58
Behavioural pharmacology of new agents. N. A. Moore 5–11
Cognitive effects in schizophrenia. Tonmoy Sharma 44–51
Genetics of novel therapeutic targets in schizophrenia. R. Kerwin and M. Owen 1–4
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky 23–33
Psychopharmacology of olanzapine. C. M. E. Stephenson and L. S. Pilowsky 52–58
Receptor alterations in schizophrenia. P. J. Harrison 12–22
Side-effects and safety profiles. Thomas R. E. Barnes and Mike A. McPhillips 34–43
Polypharmacy and early death. R. P. Snaith (C) 368. J. L. Waddington *et al* (*Authors' reply*) (C) 368–369
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265
Treatment of neuroleptic-induced akathisia with mianserin. M. Poyurovsky *et al* 238–242
see also individual names

Anxiety disorders
Meditation. P. Groves (C) 79
Quick rating of depressed mood in patients. Nigel McKenzie and Isaac Marks 266–269
see also **Panic disorder** *and* **Social phobia**

Anxiolytics
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265
Use of long-acting benzodiazepines in older people. M. Kirby (C) 460–461

Assertive community treatment
Cost-effectiveness for homeless persons with severe mental illness. Anthony F. Lehman *et al* 346–352

Attachment style
Befriending for chronic depression among women in an inner city. II. Role of fresh-start experiences and baseline psychosocial factors in remission. Tirril Harris *et al* 225–232

Attention-deficit hyperactivity disorder
Genetic basis. Anita Thapar *et al* (*Review Article*) 105–111

Barnes Akathisia Scale
Treatment of neuroleptic-induced akathisia with mianserin. M. Poyurovsky *et al* 238–242

Beck Depression Inventory
Bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. K. E. Hayford *et al* 173–178
Quick rating of depressed mood in anxiety disorders. Nigel McKenzie and Isaac Marks 266–269

Befriending
For chronic depression among women in an inner city. Tirril Harris *et al*
I. Randomised controlled trial 219–224
II. Role of fresh-start experiences and baseline psychosocial factors in remission 225–232

Behavioural disorders
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
In children. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). S. G. Gowers *et al* 413–416

Behavioural pharmacology
Of the new generation of antipsychotic agents. N. A. Moore (suppl. 38) 5–11

Benzodiazepines
Long-acting. Use in older people. M. Kirby (C) 460–461

Bereavement
Consensus criteria for traumatic grief. H. G. Prigerson *et al* (*Preliminary report*) 67–73
Criteria for traumatic grief and PTSD. G. C. Fox *et al* (C) 560. H. G. Prigerson *et al* (*Authors' reply*) (C) 560–561

Bipolar affective disorder
Early-onset. Neurodevelopmental antecedents. Engilbert Sigurdsson *et al* 121–127
Neurodevelopmental delay in the severely ill. P. McConville and N. Walker (C) 563. E. Sigurdsson and E. Fombonne (*Authors' reply*) (C) 563–564

Books
History of Lunacy and the scholarship of Edward H. Hare. Henry R. Rollin (*Editorial*) 283
Ten books. Robert Cawley 464–467

Brain
Cholinergic aspects of schizophrenia. Rajiv Tandon (suppl. 37) 7–11
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Genetics of novel therapeutic targets in schizophrenia. R. Kerwin and M. Owen (suppl. 38) 1–4
Glutamatergic aspects of schizophrenia. Carol Tamminga (suppl. 37) 12–15
Glutamatergic deficiency model of schizophrenia. A. Carlsson *et al* (suppl. 37) 2–6
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33
Lipids and schizophrenia. Nicholas P. Walker *et al* (*Editorial*) 101–104
Mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. K. A. Smith *et al* 525–529
Neurobehavioural symptoms one year after head injury. Shoumitro Deb *et al* 360–365
Olanzapine: a basic science update. Franklin Bymaster *et al* (suppl. 37) 36–40
Receptor alterations in schizophrenia. P. J. Harrison (suppl. 38) 12–22
Reduced cortical excitability in depression. P. M. Shajahan *et al* 449–454
Reduction of the parahippocampal gyrus and hippocampus in chronic schizophrenia. Kamran Razi *et al* 512–519
Schizophrenia – a disorder of the corollary discharge, feed forward systems of thought. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204
Transcranial magnetic stimulation. B. Moore (C) 273
Traumatic injury and PTSD. T. McMillan and R. R. Jacobson (C) 274–275. D. Nutt (*Author's reply*) (C) 275

Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Britain
Mental health among Irish people. D. Walsh (C) 79–80. P. Bracken *et al* (*Authors' reply*) (C) 80
see also **England, Scotland** *and* **Wales**

Bulimia nervosa
Impact of pregnancy. John Farnill Morgan *et al* 135–140

Bupropion
Efficacy for smoking cessation in smokers with a former history of major depression or alcoholism. K. E. Hayford *et al* 173–178

Cameron, D. Ewen
Early psychosis. R. Gosden (C) 461. P. McGorry (*Author's reply*) (C) 461–462

CANSAS (Camberwell Assessment of Need Short Appraisal Schedule)
HoNOS. Routine clinical outcome measures for patients with severe mental illness. Mike Slade *et al* 404–408

Cantabria First-Episode Schizophrenia Study
Three-year follow-up. José L. Vázquez-Barquero *et al* 141–149

Carers
Coping strategies in relatives of people with schizophrenia. Marcia Scazufca and Elizabeth Kuipers 154–158
Economic impact of Alzheimer's disease in the UK. E. Souêtre *et al* 51–55
Family burden of caring for people with mental illness. S. Chakrabarti and P. Kulhara (C) 463
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Of people with schizophrenia. Needs-based psychosocial intervention service. Christine Barrowclough *et al* 505–511
Satisfaction of carers at home. I. Marks (C) 369–370

Case management
Comparison of intensive and standard case management for patients with psychosis. UK700 Group 74–78

Case reports
Demise of the published case report – is resuscitation necessary? Anne Farmer (*Editorial*) 93–94
Importance in psychiatry. R. S. Shiwach (C) 565

Changing minds campaign
Stigma of mental illness. Changing minds, changing behaviour. Peter Byrne (*Editorial*) 1–2

Childhood
Contribution of Michael Rutter. I. Kolvin (*Editorial*) 471–475
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
Family intervention for intellectual disability. Paul Swamidhas Sudhakar Russell *et al* 254–258
Genetic basis of attention deficit and hyperactivity. Anita Thapar *et al* (*Review Article*) 105–111
Psychosocial adversity and psychopathology. Michael L. Rutter (*Review Article*) 480–493
Shyness and maternal social phobia. Peter J. Cooper and Marian Eke 439–443
States of over-excitability, hyper-sensitiveness, and mental explosiveness. Henry Rollin (*One hundred years ago*) 277

Childhood and adolescence
Cost-effectiveness analysis of a home-based social work intervention for deliberate self-poisoning. Sarah Byford *et al* 56–62
Glossary for HoNOSCA score sheet. S. G. Gowers *et al* 428–431
Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Brief scale for measuring outcomes of emotional and behavioural disorders. S. G. Gowers *et al* 413–416
Paddington Complexity Scale and Health of the Nation Outcome Scales for Children and Adolescents. P. Yates *et al* 417–423
Usefulness of the HoNOS. G. S. Stein (*Editorial*) 375–377
see also **Adolescence**

Cholinergic system
Cholinergic aspects of schizophrenia. Rajiv Tandon (suppl. 37) 7–11
Olanzapine: preclinical pharmacology and recent findings. Nick A. Moore (suppl. 37) 41–44

Citalopram
Sertraline. Changes in personality traits during treatment. Lisa Ekselius and Lars von Knorring 444–448

Classification
In psychiatry: ICD–10 *v.* DSM–IV. Gavin Andrews *et al* (*Editorial*) 3–5

Clients
'Patient *v.* client'. A. D. Jager (C) 180

Client Satisfaction Questionnaire
Satisfaction with in-patient psychiatric services. Nan Greenwood *et al* 159–163

Clinical Global Impression scale
HoNOS: a case study in general psychiatry. Vimal K. Sharma *et al* 395–398

Clinical Interview Schedule–Revised
Neurobehavioural symptoms one year after head injury. Shoumitro Deb *et al* 360–365

Clozapine
An approach to treatment resistance in schizophrenia. Stephen R. Marder (suppl. 37) 19–22
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Cognitive effects of antipsychotics in schizophrenia. Tonmoy Sharma (suppl. 38) 44–51
Schizophrenia and diabetes mellitus. D. Mohan *et al* (C) 180–181
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43

Cognitive–behavioural therapy
And moclobemide, for panic disorder with agoraphobia. B. Loerch *et al* 205–212
Durability of effects in chronic schizophrenia. Nicholas Tarrier *et al* 500–504
Psychological treatments for hypochondriasis. I. Marks (C) 367. D. M. Clark and P. M. Salkovskis (*Authors' reply*) (C) 367–368

Cognitive impairment
Anorexia nervosa as a phenotype of cognitive impairment in schizophrenia. Y. Yamashita *et al* (C) 558
Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. K. A. Smith *et al* 525–529
Cognitive disability and direct care costs for elderly people. Shane Kavanagh and Martin Knapp 539–546
Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Tonmoy Sharma (suppl. 38) 44–51
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Hypertension and cognitive decline. Robert Stewart (*Editorial*) 286–287
In schizophrenia, and its neurochemical basis. Alan Breier (suppl. 37) 16–18
see also **Dementia**

Combinatorial chemistry
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25

Community care
Between prison and the community. Luke Birmingham (*Editorial*) 378–379
Comparison of intensive and standard case management for patients with psychosis. UK700 Group 74–78
Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Anthony F. Lehman *et al* 346–352
Effectiveness of community psychiatry. A. P. Boardman (C) 179
Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
Homicides: the evidence. G. Szmukler *et al* (C) 564–565
Satisfaction of carers at home. I. Marks (C) 369–370

Computers
Clinical outcome measurement. J. Taylor (C) 179

Coping strategies
In relatives of people with schizophrenia. Marcia Scazufca and Elizabeth Kuipers 154–158

Cornwall
County-wide survey of repeat prescription of hypnotics. M. Wilcock *et al* (C) 277

Corollary discharge–feed forward (CD–FF) systems of thought
Pathophysiology of schizophrenia. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204

Corrigenda 278

Costs *see* **Economics**

Creativity
Contribution of Michael Rutter. I. Kolvin (*Editorial*) 471–475

Criminality *see* **Offenders**

Criteria for dementia with Lewy bodies (CDLB)
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Cultures
Cross-cultural comparison of depressive symptoms does not support stereotypes of ageing. J. R. M. Copeland *et al* (*EURODEP Study*) 322–329
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38

Dangerousness
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Medico-legal notes. Henry Rollin (*One hundred years ago*) 463

Deliberate self-harm
Cost-effectiveness of a home-based social work intervention for children and adolescents. Sarah Byford *et al* 56–62
Orphenadrine. Lars Slørdal and Pål Gjerden (C) 275–276
see also **Suicide**

Delusions
Schizophrenia – a disorder of the corollary discharge, feed forward systems of thought. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204
Serious sex offending against women by men with schizophrenia. Alan D. Smith and Pamela J. Taylor 233–237

Dementia
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Cognitive disability and direct care costs for elderly people. Shane Kavanagh and Martin Knapp 539–546
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Economic impact of Alzheimer's disease in the UK. E. Souêtre *et al* 51–55
Hypertension and cognitive decline. Robert Stewart (*Editorial*) 286–287
Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479
Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Clive Holmes *et al* 45–50

Depression
Aetiology
Amiodarone-induced depression. A. Ambrose and E. Salib (C) 366–367
Development of obsessive and depressive symptoms during risperidone treatment. B. Panagiotis *et al* (C) 559
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120

Complications
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. K. E. Hayford *et al* 173–178
Cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Predictors of chronic PTSD. Sara A. Freedman *et al* 353–359
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265
Quick rating of depressed mood in anxiety disorders. Nigel McKenzie and Isaac Marks 266–269

Epidemiology **see EURODEP Study**

Nosology
'Subthreshold' mental disorders. Review and synthesis of studies on minor depression and other 'brand names'. Harold Alan Pincus *et al* (*Review Article*) 288–296

Pathophysiology
Brain mechanisms associated with relapse and associated cognitive impairment following acute tryptophan depletion. K. A. Smith *et al* 525–529
Reduced cortical excitability. P. M. Shajahan *et al* 449–454

Psychology
Brain mechanisms associated with relapse and associated cognitive impairment following acute tryptophan depletion. K. A. Smith *et al* 525–529
Family burden. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38

Scales
Depression symptoms in late life assessed using the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 339–345
Development of the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 330–338
Quick rating of depressed mood in anxiety disorders. Nigel McKenzie and Isaac Marks 266–269

Therapy
Befriending for women in an inner city. Tirril Harris *et al*
I. Randomised controlled trial 219–224
II. Role of fresh-start experiences and baseline psychosocial factors in remission 225–232

Definitions of depression. P. Tharyan and G. Raghuthaman (C) 559–560
Medication received by patients following the acute episode. Rajini Ramana *et al* 128–134
Mirtazepine causing hyperphagia. R. T. Abed and M. Cooper (C) 181
Olanzapine in the treatment of psychotic depression. G. S. Malhi and S. A. Checkley (C) 460
see also **Antidepressants**

Developing countries
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258
Fever and acute brief psychosis in urban and rural settings in north India. Pamela Y. Collins *et al* 520–524

Diabetes mellitus
Schizophrenia. D. Mohan *et al* (C) 180–181

Diagnoses
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Victor Peralta and Manuel J. Cuesta 243–248
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Disability
Cognitive disability and direct care costs for elderly people. Shane Kavanagh and Martiń Knapp 539–546

Disability Assessment Schedule
Cantabria First-Episode Schizophrenia Study. José L. Vázquez-Barquero *et al* 141–149

Donepezil hydrochloride
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479

Dopamine
Behavioural pharmacology of new antipsychotics. N. A. Moore (suppl. 38) 5–11

Dopamine DRD-4 receptor gene
Genetic basis of attention deficit and hyperactivity. Anita Thapar *et al* (*Review Article*) 105–111

Dopamine receptors
Genetics of novel therapeutic targets in schizophrenia. R. Kerwin and M. Owen (suppl. 38) 1–4
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33
Olanzapine: a basic science update. Franklin Bymaster *et al* (suppl. 37) 36–40
Receptor alterations in schizophrenia. P. J. Harrison (suppl. 38) 12–22

Dopamine transporter gene
Genetic basis of attention deficit and hyperactivity. Anita Thapar *et al* (*Review Article*) 105–111

Drug misuse
Hair analysis for substance use. G. Haddock *et al* (C) 370
Orphenadrine – presence in patients not using antipsychotics. A. Macdonald (C) 565
Prevalence of substance misuse in first-episode psychosis. Roch Cantwell *et al* 150–153

Drugs
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265
see also **Amiodarone, Amphetamine, Anticholinergics, Antidepressants, Antipsychotics, Benzodiazepines, Bupropion, Citalopram, Clozapine, Fluoxetine, Haloperidol, Hypnotics, Melatonin, Mianserin, Mirtazepine, Moclobemide, Olanzapine, Orphenadrine, Risperidone, Sertraline** *and* **Tryptophan**

DSM–III
Aetiological risk factors for personality disorders. Jeremy W. Coid 530–538

DSM–III–R
Coping strategies in relatives of people with schizophrenia. Marcia Scazufca and Elizabeth Kuipers 154–158
Definitions of schizophrenia. M. B. First and H. A. Pincus (C) 273
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Victor Peralta and Manuel J. Cuesta 243–248
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
Olanzapine *v.* haloperidol in the treatment of schizoaffective disorder. Pierre V. Tran *et al* 15–22

DSM–IV
Aetiological risk factors for personality disorders. Jeremy W. Coid 530–538
Reduced cortical excitability in depression. P. M. Shajahan *et al* 449–454
v. ICD–10. Classification in psychiatry. Gavin Andrews *et al* (*Editorial*) 3–5

Early psychosis
R. Gosden (C) 461. P. McGorry (*Author's reply*) (C) 461–462

Eating Disorder Examination
Impact of pregnancy on bulimia nervosa. John Farnill Morgan *et al* 135–140

Eating disorders
Anorexia nervosa as a phenotype of cognitive impairment in schizophrenia. Y. Yamashita *et al* (C) 558
Difficulties in family functioning and adolescent anorexia nervosa. Simon Gowers and Clive North 63–66
Impact of pregnancy on bulimia nervosa. John Farnill Morgan *et al* 135–140
Mirtazepine causing hyperphagia. R. T. Abed and M. Cooper (C) 181

Economics
Cognitive disability and direct care costs for elderly people. Shane Kavanagh and Martin Knapp 539–546
Cost-effectiveness analysis of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Sarah Byford *et al* 56–62
Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Anthony F. Lehman *et al* 346–352
Impact of Alzheimer's disease in the UK. Cost of care and disease severity for non-institutionalised patients. E. Souêtre *et al* 51–55

ECT *see* **Electroconvulsive therapy**

Edinburgh High-Risk Study
People at risk of schizophrenia. Sample characteristics of the first 100 cases. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557

Edinburgh Rehabilitation Status Scale
Neurobehavioural symptoms one year after head injury. Shoumitro Deb *et al* 360–365

Elderly
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
Cognitive disability and direct care costs. Shane Kavanagh and Martin Knapp 539–546
County-wide survey of repeat prescription of hypnotics. M. Wilcock *et al* (C) 277
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Economic impact of Alzheimer's disease in the UK. E. Souêtre *et al* 51–55
Glossary for HoNOS 65+ score sheet. A. Burns *et al* 435–438
Health of the Nation Outcome Scales for Elderly People (HoNOS 65+). A. Burns *et al* 424–427
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479
Use of long-acting benzodiazepines. M. Kirby (C) 460–461
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50
see also **EURODEP Study**

Electroconvulsive therapy
Motor seizure monitoring. Prashanth M. Mayur *et al* 270–272

Electroencephalogram monitoring
Motor seizure monitoring during ECT. Prashanth M. Mayur *et al* 270–272

Emotion
Emotional functions and cognitive processes. D. M. Barbenel (C) 462. S. F. Taylor and I. Liberzon (*Authors' reply*) (C) 462–463
Paying attention to emotion in schizophrenia. Stephan F. Taylor and Israel Liberzon (*Editorial*) 6–8

England
And Wales. Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
County-wide survey of repeat prescription of hypnotics. M. Wilcock *et al* (C) 277
Homicides and community care: the evidence. G. Szmukler *et al* (C) 564–565
Mental health care failure. Tom Burns and Stefan Priebe (*Editorial*) 191–192

Epidemiological research
Two-phase epidemiological surveys in psychiatry. Graham Dunn *et al* (*Editorial*) 95–100

Ethnicity
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Mental health among Irish people living in Britain. D. Walsh (C) 79–80. P. Bracken *et al* (*Authors' reply*) (C) 80

Euro-Americans
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38

EURODEP Study
Cross-cultural comparison of symptoms does not support stereotypes of ageing. J. R. M. Copeland *et al* 322–329
Depression in Europe. Geographical distribution among older people. J. R. M. Copeland *et al* 312–321
Depression of older age. Origins of the study. J. R. M. Copeland 304–306
Depression symptoms in late life assessed using the EURO–D Scale. Effect of age, gender and marital status. M. J. Prince *et al* 339–345
Development of the EURO–D scale. M. J. Prince *et al* 330–338
EURODEP Consortium and late-life depression. Dan Blazer (*Editorial*) 284–285
Review of community prevalence of depression in later life. A. T. F. Beekman *et al* 307–311

EURO–D scale
Depression of older age. Origins of the study. J. R. M. Copeland (*EURODEP Study*) 304–306
Depression symptoms in late life assessed using the scale. Effect of age, gender and marital status. M. J. Prince *et al* (*EURODEP Study*) 339–345
Development of the scale. M. J. Prince *et al* (*EURODEP Study*) 330–338

Examinations
Eating Disorder Examination 135–140
Mini-Mental State Examination 39–44, 51–55, 249–253
Present Behavioural Examination 39–44
Present State Examination 141–149, 219–224, 547–553

Expressed emotion
Coping strategies in relatives of people with schizophrenia. Marcia Scazufca and Elizabeth Kuipers 154–158

Families
Burden of caring for people with mental illness. S. Chakrabarti and P. Kulhara (C) 463
Burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Co-occurrence of polydactyly and psychosis. N. Purandare and S. Plunkett (C) 460
Coping strategies in relatives of people with schizophrenia. Marcia Scazufca and Elizabeth Kuipers 154–158
Difficulties in functioning and adolescent anorexia nervosa. Simon Gowers and Clive North 63–66
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557
Satisfaction of carers at home. I. Marks (C) 369–370

Family Assessment Device
Difficulties in family functioning and adolescent anorexia nervosa. Simon Gowers and Clive North 63–66

Family therapy
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258
Needs-based psychosocial intervention service for carers of people with schizophrenia. Christine Barrowclough *et al* 505–511

Farmers
Suicide. R. A. Collacott (C) 369. K. Hawton (*Author's reply*) (C) 369

Feighner criteria
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Victor Peralta and Manuel J. Cuesta 243–248

Fever
And acute brief psychosis in urban and rural settings in north India. Pamela Y. Collins *et al* 520–524

Firearms
Suicide in farmers. R. A. Collacott (C) 369. K. Hawton (*Author's reply*) (C) 369

First-rank symptoms
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Victor Peralta and Manuel J. Cuesta 243–248

Fluoxetine
Continuing treatment of panic disorder after acute response. David Michelson *et al* 213–218
Development of obsessive and depressive symptoms during risperidone treatment. B. Panagiotis *et al* (C) 559

Forensic psychiatry *see* **Offenders**

Gender differences
County-wide survey of repeat prescription of hypnotics. M. Wilcock *et al* (C) 277
Cross-cultural comparison of depressive symptoms does not support stereotypes of ageing. J. R. M. Copeland *et al* (*EURODEP Study*) 322–329
Depression in Europe. Geographical distribution among older people. J. R. M. Copeland *et al* (*EURODEP Study*) 312–321
Depression symptoms in late life assessed using the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 339–345
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265

General psychiatry
HoNOS: a case study. Vimal K. Sharma *et al* 395–398

Genetics
Basis of attention deficit and hyperactivity. Anita Thapar *et al* (*Review Article*) 105–111
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25
Of novel therapeutic targets in schizophrenia. R. Kerwin and M. Owen (suppl. 38) 1–4
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557
Psychosocial adversity and child psychopathology. Michael L. Rutter (*Review Article*) 480–493
Receptor alterations in schizophrenia. P. J. Harrison (suppl. 38) 12–22

Glutamate
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Glutamatergic aspects of schizophrenia. Carol Tamminga (suppl. 37) 12–15
Glutamatergic deficiency model of schizophrenia. A. Carlsson *et al* (suppl. 37) 2–6
Olanzapine: preclinical pharmacology and recent findings. Nick A. Moore (suppl. 37) 41–44
Traumatic brain injury and PTSD. T. McMillan and R. R. Jacobson (C) 274–275. D. Nutt (*Author's reply*) (C) 275

GMS–AGECAT
Cross-cultural comparison of depressive symptoms does not support stereotypes of ageing. J. R. M. Copeland *et al* (*EURODEP Study*) 322–329
Depression in Europe. Geographical distribution among older people. J. R. M. Copeland *et al* (*EURODEP Study*) 312–321
Depression of older age. Origins of the study. J. R. M. Copeland (*EURODEP Study*) 304–306
Development of the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 330–338

Grief
Consensus criteria for traumatic grief. H. G. Prigerson *et al* (*Preliminary report*) 67–73
Criteria for traumatic grief and PTSD. G. C. Fox *et al* (C) 560. H. G. Prigerson *et al* (*Authors' reply*) (C) 560–561

Hair analysis
For substance use. G. Haddock *et al* (C) 370

Hair loss
Sudden loss due to mental shock. Henry Rollin (*One hundred years ago*) 80

Hallucinations
Schizophrenia – a disorder of the corollary discharge, feed forward systems of thought. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204
Serious sex offending against women by men with schizophrenia. Alan D. Smith and Pamela J. Taylor 233–237

Haloperidol
An approach to treatment resistance in schizophrenia. Stephen R. Marder (suppl. 37) 19–22
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Olanzapine *v.* haloperidol in the treatment of schizoaffective disorder. Pierre V. Tran *et al* 15–22
Tardive dyskinesia in patients with schizophrenia during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30

Hamilton Anxiety rating scale
Continuing treatment of panic disorder after acute response: trial with fluoxetine. David Michelson *et al* 213–218

Hamilton Depression rating scale
Continuing treatment of panic disorder after acute response: trial with fluoxetine. David Michelson *et al* 213–218

Hare, Edward H.
History of Lunacy and scholarship. Henry R. Rollin (*Editorial*) 283

Head injury
Neurobehavioural symptoms one year after. Shoumitro Deb *et al* 360–365

Health of the Nation Outcome Scales (HoNOS)
A case study in general psychiatry. Vimal K. Sharma *et al* 395–398
CANSAS. Routine clinical outcome measures for patients with severe mental illness. Mike Slade *et al* 404–408
Clinical outcome measurement. J. Taylor (C) 179
Glossary for score sheet. J. Wing *et al* 432–434
Reliability and validity in a three-year follow-up of first-onset psychosis. S. Amin *et al* 399–403
Results of the Victorian field trial. T. Trauer *et al* 380–388
Usefulness. G. S. Stein (*Editorial*) 375–377
Validation. Paul Bebbington *et al* 389–394
Validity and reliability in patients in the community. Martin Orrell *et al* 409–412

Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA)
And Paddington Complexity Scale. P. Yates *et al* 417–423
Brief scale for measuring outcomes of emotional and behavioural disorders in children. S. G. Gowers *et al* 413–416
Glossary for score sheet. S. G. Gowers *et al* 428–431
Usefulness of the HoNOS. G. S. Stein (*Editorial*) 375–377

Health of the Nation Outcome Scales for Elderly People (HoNOS 65+)
A. Burns *et al* 424–427
Glossary for score sheet . A. Burns *et al* 435–438

Usefulness of the HoNOS. G. S. Stein (*Editorial*) 375–377

Hippocampus
And parahippocampal gyrus. Reduction in patients with chronic schizophrenia. Kamran Razi *et al* 512–519

Homelessness
Cost-effectiveness of assertive community treatment for severe mental illness. Anthony F. Lehman *et al* 346–352

Home treatment
Cost-effectiveness of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Sarah Byford *et al* 56–62
Satisfaction of carers at home. I. Marks (C) 369–370

Homicide
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
And community care: the evidence. G. Szmukler *et al* (C) 564–565
By people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
Unreliable admissions. Case of misdiagnosis of amnesia and misuse of abreaction technique. Gisli H. Gudjonsson *et al* 455–459

HoNOS *see* **Health of the Nation Outcome Scales**

Hungary
Focus on psychiatry. László Tringer 81–85

5-Hydroxytryptamine *see* **Serotonin**

Hyperactivity
Genetic basis. Anita Thapar *et al* (*Review Article*) 105–111

Hyperphagia
And mirtazepine. R. T. Abed and M. Cooper (C) 181

Hypertension
And cognitive decline. Robert Stewart (*Editorial*) 286–287

Hypnotics
County-wide survey of repeat prescription. M. Wilcock *et al* (C) 277
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265

Hypochondriasis
Psychological treatments. I. Marks (C) 367. D. M. Clark and P. M. Salkovskis (*Authors' reply*) (C) 367–368

ICD–10
Definitions of schizophrenia. M. B. First and H. A. Pincus (C) 273
Fever and acute brief psychosis in north India. Pamela Y. Collins *et al* 520–524
Prevalence of substance misuse in first-episode psychosis. Roch Cantwell *et al* 150–153
v. DSM–IV. Classification in psychiatry. Gavin Andrews *et al* (*Editorial*) 3–5

ICD–10 Research Diagnostic Criteria
Neurodevelopmental antecedents of early-onset bipolar affective disorder. Engilbert Sigurdsson *et al* 121–127

India
Beginning and end of psychiatric pathways. S. C. Pradhan and M. Meghachandra Singh (C) 276
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258
Fever and acute brief psychosis in urban and rural settings. Pamela Y. Collins *et al* 520–524

In-patients
Satisfaction with psychiatric services. Nan Greenwood *et al* 159–163

Intellectual disability
Family intervention for children. Paul Swamidhas Sudhakar Russell *et al* 254–258

Interactive Group Psychoeducation
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258

Interviews
McMaster's Structured Interview of Family Functioning 63–66
Structured Clinical Interview for DSM–III–R 135–140

Inventories
Beck Depression Inventory 173–178, 266–269
Structured Inventory for Schizotypy 547–553

IQ
Neurodevelopmental antecedents of early-onset bipolar affective disorder. Engilbert Sigurdsson *et al* 121–127
Neurodevelopmental delay in the severely ill. P. McConville and N. Walker (C) 563. E. Sigurdsson and E. Fombonne (*Authors' reply*) (C) 563–564

Irish
Mental health among Irish people living in Britain. D. Walsh (C) 79–80. P. Bracken *et al* (*Authors' reply*) (C) 80

Jet-lag
De novo psychosis. G. Katz *et al* (C) 558–559

Journals
Demise of the published case report – is resuscitation necessary? Anne Farmer (*Editorial*) 93–94
Importance of case reports in psychiatry. R. S. Shiwach (C) 565

Karolinska Scales of Personality
Personality changes with sertraline or citalopram. Lisa Ekselius and Lars von Knorring 444–448

Latinos
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38

Learning disabilities
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258

Lewy body dementia
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Life events
Befriending for chronic depression among women in an inner city. II. Role of fresh-start experiences and baseline psychosocial factors in remission. Tirril Harris *et al* 225–232

Life Events Schedule
Fever and acute brief psychosis in north India. Pamela Y. Collins *et al* 520–524

Lipids
And schizophrenia. Nicholas P. Walker *et al* (*Editorial*) 101–104

McMaster's Structured Interview of Family Functioning
Difficulties in family functioning and adolescent anorexia nervosa. Simon Gowers and Clive North 63–66

Magnetic resonance imaging
Reduction of the parahippocampal gyrus and hippocampus in chronic schizophrenia. Kamran Razi *et al* 512–519

Marital status
Depression symptoms in late life assessed using the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 339–345

Media
Lunatics at large and the public press. Henry Rollin (*One hundred years ago*) 370

Medication *see* **Drugs**

Medico-Psychological Association of Britain and Ireland
Henry Rollin (*One hundred years ago*) 181–182

Meditation
And anxiety. P. Groves (C) 79

Melatonin
De novo jet-lag psychosis. G. Katz *et al* (C) 558–559

Memory
Traumatic brain injury and PTSD. T. McMillan and R. R. Jacobson (C) 274–275. D. Nutt (*Author's reply*) (C) 275

Memory distrust syndrome
Unreliable admissions to homicide. Gisli H. Gudjonsson *et al* 455–459

Men
Cantabria First-Episode Schizophrenia Study: three-year follow-up. José L. Vázquez-Barquero *et al* 141–149
Prevalence of substance misuse in first-episode psychosis. Roch Cantwell *et al* 150–153
With schizophrenia. Serious sex offending against women. Alan D. Smith and Pamela J. Taylor 233–237
see also **Gender differences**

Mental health
Among Irish people living in Britain. D. Walsh (C) 79–80. P. Bracken *et al* (*Authors' reply*) (C) 80

Mental health legislation
Lunatics at large and the public press. Henry Rollin (*One hundred years ago*) 370

Mental health review tribunals
Limits to value for offender patients. Pamela J. Taylor *et al* 164–169

Mental health services
Befriending for chronic depression among women in an inner city. I. & II. Tirril Harris *et al* 219–224, 225–232
Beginning and end of psychiatric pathways. S. C. Pradhan and M. Meghachandra Singh (C) 276
Cognitive disability and direct care costs for elderly people. Shane Kavanagh and Martin Knapp 539–546
Focus on psychiatry in Hungary. László Tringer 81–85
Mental health care failure in England. Tom Burns and Stefan Priebe (*Editorial*) 191–192
Needs-based psychosocial intervention service for carers of people with schizophrenia. Christine Barrowclough *et al* 505–511
Satisfaction with in-patient psychiatric services. Nan Greenwood *et al* 159–163
Satisfied with dissatisfaction? A. Key *et al* (C) 273–274
see also **Community care**

Mental illness *see* **Psychiatric disorders**

Mianserin
Treatment of neuroleptic-induced akathisia. M. Poyurovsky *et al* 238–242

Mini-Mental State Examination
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44
Depression, cerebral atrophy, cognitive performance and incidence of dementia. Sigurdur Pálsson *et al* 249–253
Economic impact of Alzheimer's disease in the UK. E. Souêtre *et al* 51–55

Mirtazepine
Causing hyperphagia. R. T. Abed and M. Cooper (C) 181

Moclobemide
And cognitive–behavioural therapy, for panic disorder with agoraphobia. B. Loerch *et al* 205–212

Morgan–Russell Outcome Assessment Schedule
Difficulties in family functioning and adolescent anorexia nervosa. Simon Gowers and Clive North 63–66

Mortality
Antipsychotic polypharmacy and early death. R. P. Snaith (C) 368. J. L. Waddington *et al* (*Authors' reply*) (C) 368–369
Orphenadrine. Lars Slørdal and Pål Gjerden (C) 275–276
see also **Suicide**

Mothers
Childhood shyness and maternal social phobia. Peter J. Cooper and Marian Eke 439–443

Motor-evoked potentials
Reduced cortical excitability in depression. P. M. Shajahan *et al* 449–454

Motor seizure monitoring
During ECT. Prashanth M. Mayur *et al* 270–272

National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS–ADRDA) criteria
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement Neurosciences (NINDS–AIREN) criteria
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Neurobehavioural symptoms
One year after head injury. Shoumitro Deb *et al* 360–365

Neurodevelopmental impairment
Antecedents of early-onset bipolar affective disorder. Engilbert Sigurdsson *et al* 121–127
Neurodevelopmental delay in the severely ill. P. McConville and N. Walker (C) 563. E. Sigurdsson and E. Fombonne (*Authors' reply*) (C) 563–564

Neuroleptics *see* **Antipsychotics**

Newcastle Thousand Family Study
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120

N-methyl-D-aspartate (NMDA) receptor
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Glutamatergic aspects of schizophrenia. Carol Tamminga (suppl. 37) 12–15
Glutamatergic deficiency model of schizophrenia. A. Carlsson *et al* (suppl. 37) 2–6
Olanzapine: preclinical pharmacology and recent findings. Nick A. Moore (suppl. 37) 41–44

Object relations
Developing theoretically relevant measures of psychoanalytic constructs. A. S. Joyce *et al* (C) 179–180

Obsessive symptoms
And depressive symptoms. Development during risperidone treatment. B. Panagiotis *et al* (C) 559

Offenders
Aetiological risk factors for personality disorders. Jeremy W. Coid 530–538
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Between prison and the community. Luke Birmingham (*Editorial*) 378–379
Homicides and community care: the evidence. G. Szmukler *et al* (C) 564–565

Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
Limits to the value of mental health review tribunals for offender patients. Pamela J. Taylor *et al* 164–169
Lunatics at large and the public press. Henry Rollin (*One hundred years ago*) 370
Medico-legal notes. Henry Rollin (*One hundred years ago*) 463
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553
Serious sex offending against women by men with schizophrenia. Alan D. Smith and Pamela J. Taylor 233–237
Unreliable admissions to homicide. Gisli H. Gudjonsson *et al* 455–459

Olanzapine
An approach to treatment resistance in schizophrenia. Stephen R. Marder (suppl. 37) 19–22
Basic science update. Franklin Bymaster *et al* (suppl. 37) 36–40
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
In the long-term treatment of schizophrenia. John Kane (suppl. 37) 26–29
In the treatment of psychotic depression. G. S. Malhi and S. A. Checkley (C) 460
Preclinical pharmacology and recent findings. Nick A. Moore (suppl. 37) 41–44
Psychopharmacology. C. M. E. Stephenson and L. S. Pilowsky (suppl. 38) 52–58
Review of recent clinical studies. Gary D. Tollefson and Amy J. Kuntz (suppl. 37) 30–35
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43
Tardive dyskinesia in patients with schizophrenia during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30
v. haloperidol in the treatment of schizoaffective disorder. Pierre V. Tran *et al* 15–22

Old age *see* Elderly

One hundred years ago
Henry Rollin
Growth of insanity in Scotland 565–566
Lunatics at large and the public press 370
Medico-legal notes 463
Medico-Psychological Association of Britain and Ireland 181–182
States of over-excitability, hyper-sensitiveness, and mental explosiveness in children 277
Sudden loss of hair due to mental shock 80

Orphenadrine
Lars Slørdal and Pål Gjerden (C) 275–276
Presence in patients not using antipsychotics. A. Macdonald (C) 565

Outcome measurement
Clinical outcome measurement. J. Taylor (C) 179
see also Health of the Nation Outcome Scales

Paddington Complexity Scale
And Health of the Nation Outcome Scales for Children and Adolescents. P. Yates *et al* 417–423

Panic disorder
Continuing treatment after acute response: trial with fluoxetine. David Michelson *et al* 213–218
With agoraphobia. Moclobemide and cognitive–behavioural therapy. B. Loerch *et al* 205–212

Parahippocampal gyrus
And hippocampus. Reduction in patients with chronic schizophrenia. Kamran Razi *et al* 512–519

Parental Attitude Scale towards the Management of Intellectual Disability
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258

Parenting
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120

Parkinsonism
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43

Pathways to care
Beginning and end of psychiatric pathways. S. C. Pradhan and M. Meghachandra Singh (C) 276

Patients
Limits to the value of mental health review tribunals for offender patients. Pamela J. Taylor *et al* 164–169
'Patient *v.* client'. A. D. Jager (C) 180
Satisfaction with in-patient psychiatric services. Nan Greenwood *et al* 159–163
Satisfied with dissatisfaction? A. Key *et al* (C) 273–274
The difficult patient. Role of 'scientific psychiatry' in understanding patients with chronic schizophrenia or severe personality disorder. R. D. Hinshelwood (*Editorial*) 187–190

Personality disorders
Aetiological risk factors. Jeremy W. Coid 530–538
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
The difficult patient. Role of 'scientific psychiatry' in understanding patients with chronic schizophrenia or severe personality disorder. R. D. Hinshelwood (*Editorial*) 187–190

Personality traits
Changes during treatment with sertraline or citalopram. Lisa Ekselius and Lars von Knorring 444–448

Polydactyly
Co-occurrence with psychosis. N. Purandare and S. Plunkett (C) 460

Polypharmacy
Antipsychotic polypharmacy and early death. R. P. Snaith (C) 368. J. L. Waddington *et al* (*Authors' reply*) (C) 368–369

Polyunsaturated fatty acids
Lipids and schizophrenia. Nicholas P. Walker *et al* (*Editorial*) 101–104

Positron emission tomography
Brain mechanisms associated with depressive relapse following acute tryptophan depletion. K. A. Smith *et al* 525–529
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Glutamatergic aspects of schizophrenia. Carol Tamminga (suppl. 37) 12–15
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33

Post-traumatic stress disorder
Criteria for traumatic grief and PTSD. G. C. Fox *et al* (C) 560. H. G. Prigerson *et al* (*Authors' reply*) (C) 560–561
Predictors of chronic PTSD. Sara A. Freedman *et al* 353–359
Traumatic brain injury. T. McMillan and R. R. Jacobson (C) 274–275. D. Nutt (*Author's reply*) (C) 275
Unconsciousness. H. L. Freeman (C) 79

Pregnancy
Impact on bulimia nervosa. John Farnill Morgan *et al* 135–140

Present Behavioural Examination
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44

Present State Examination
Befriending for chronic depression among women in an inner city. I. Tirril Harris *et al* 219–224

Cantabria First-Episode Schizophrenia Study. José L. Vázquez-Barquero *et al* 141–149
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553

PRiSM study
Effectiveness of community psychiatry. A. P. Boardman (C) 179

Prisoners
Between prison and the community. Luke Birmingham (*Editorial*) 378–379

Psychiatric disorders
Assertive community treatment for homeless persons with severe mental illness. Anthony F. Lehman *et al* 346–352
Family burden of caring for people with mental illness. S. Chakrabarti and P. Kulhara (C) 463
Growth of insanity in Scotland. Henry Rollin (*One hundred years ago*) 565–566
Homicides and community care: the evidence. G. Szmukler *et al* (C) 564–565
Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
Lunatics at large and the public press. Henry Rollin (*One hundred years ago*) 370
Routine clinical outcome measures for patients with severe mental illness: CANSAS and HoNOS. Mike Slade *et al* 404–408
Stigma of mental illness. Peter Byrne (*Editorial*) 1–2
'Subthreshold'. Studies on minor depression and other 'brand names'. Harold Alan Pincus *et al* (*Review Article*) 288–296

Psychiatry
Classification: ICD–10 *v.* DSM–IV. Gavin Andrews *et al* (*Editorial*) 3–5
Focus on psychiatry in Hungary. László Tringer 81–85
Importance of case reports. R. S. Shiwach (C) 565
The difficult patient. Role of 'scientific psychiatry' in understanding patients with chronic schizophrenia or severe personality disorder. R. D. Hinshelwood (*Editorial*) 187–190

Psychoanalysis
Developing theoretically relevant measures of constructs. A. S. Joyce *et al* (C) 179–180

Psychoeducation
Family intervention for intellectually disabled children. Paul Swamidhas Sudhakar Russell *et al* 254–258

Psychosis
Comparison of intensive and standard case management. UK700 Group 74–78
Co-occurrence of polydactyly. N. Purandare and S. Plunkett (C) 460
De novo jet-lag psychosis. G. Katz *et al* (C) 558–559
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparison between schizophrenic and non-schizophrenic psychotic disorders. Victor Peralta and Manuel J. Cuesta 243–248
Early psychosis. R. Gosden (C) 461. P. McGorry (*Author's reply*) (C) 461–462
Fever and acute brief psychosis in urban and rural settings in north India. Pamela Y. Collins *et al* 520–524
First-episode. Prevalence of substance misuse. Roch Cantwell *et al* 150–153
HoNOS. Reliability and validity in a three-year follow-up of first-onset psychosis. S. Amin *et al* 399–403
Olanzapine in the treatment of psychotic depression. G. S. Malhi and S. A. Checkley (C) 460
Risperidone treatment of amphetamine psychosis. A. Jha and H. Fourie (C) 366
Serious sex offending against women by men with schizophrenia. Relationship of illness and psychotic symptoms to offending. Alan D. Smith and Pamela J. Taylor 233–237
see also **Antipsychotics**

Psychotherapy
Developing theoretically relevant measures of psychoanalytic constructs. A. S. Joyce *et al* (C) 179–180
Meditation and anxiety. P. Groves (C) 79
Psychological treatments for hypochondriasis. I. Marks (C) 367. D. M. Clark and P. M. Salkovskis (*Authors' reply*) (C) 367–368
see also **Befriending, Cognitive–behavioural therapy** *and* **Family therapy**

Psychotic depression
Olanzapine in treatment. G. S. Malhi and S. A. Checkley (C) 460

PTSD *see* **Post-traumatic stress disorder**

Puerperium
Impact of pregnancy on bulimia nervosa. John Farnill Morgan *et al* 135–140

QOR (quality of object relations) scale
Developing theoretically relevant measures of psychoanalytic constructs. A. S. Joyce *et al* (C) 179–180

Rating scales *see* **Scales**

Relatives *see* **Families**

Research Diagnostic Criteria for Tardive Dyskinesia
Patients with schizophrenia during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30

Risperidone
An approach to treatment resistance in schizophrenia. Stephen R. Marder (suppl. 37) 19–22
Cognitive deficit in schizophrenia and its neurochemical basis. Alan Breier (suppl. 37) 16–18
Cognitive effects of antipsychotics in schizophrenia. Tonmoy Sharma (suppl. 38) 44–51
Development of obsessive and depressive symptoms during treatment. B. Panagiotis *et al* (C) 559
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43
Treatment of amphetamine psychosis. A. Jha and H. Fourie (C) 366

Rivastigmine
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479

Royal College of Psychiatrists
Stigma of mental illness. Changing minds, changing behaviour. Peter Byrne (*Editorial*) 1–2

Rural populations
Fever and acute brief psychosis in north India. Pamela Y. Collins *et al* 520–524
Suicide in farmers. R. A. Collacott (C) 369. K. Hawton (*Author's reply*) (C) 369

Rutter, Michael
Contribution. I. Kolvin (*Editorial*) 471–475
Talking with him. I. Kolvin (*Interview*) 494–499

SafetyNet Millennium
Clinical outcome measurement. J. Taylor (C) 179

Scales
Abnormal Involuntary Movement Scale 23–30
Barnes Akathisia Scale 238–242

Clinical Global Impression scale 395–398
Edinburgh Rehabilitation Status Scale 360–365
EURO-D scale 304–306, 330–338, 339–345
Hamilton Anxiety rating scale 213–218
Hamilton Depression rating scale 213–218
Karolinska Scales of Personality 444–448
Paddington Complexity Scale 417–423
Parental Attitude Scale towards the Management of Intellectual Disability 254–258
QOR (quality of object relations) scale (C) 179–180
Quick rating of depressed mood in anxiety disorders. Nigel McKenzie and Isaac Marks 266–269
Scales for the Assessment of Negative and Positive Symptoms 141–149
Verona Service Satisfaction Scale (C) 273–274
see also **Client Satisfaction Questionnaire, Examinations, Family Assessment Device, GMS–AGECAT, HoNOS, HoNOS 65+, HoNOSCA, ICD–10 Research Diagnostic Criteria, Interviews, Inventories, Research Diagnostic Criteria for Tardive Dyskinesia, Schedules** *and* **SCL–90–R**

Schedules
CANSAS (Camberwell Assessment of Need Short Appraisal Schedule) 404–408
Clinical Interview Schedule–Revised 360–365
Disability Assessment Schedule 141–149
Life Events Schedule 520–524
Morgan–Russell Outcome Assessment Schedule 63–66
Schedule for Affective Disorders and Schizophrenia (SADS–L) (*Preliminary report*) 547–553
Schedules for Clinical Assessment in Neuropsychiatry 389–394
Social Behaviour Schedule 389–394
Social Role Performance Schedule 389–394

Schizoaffective disorder
Olanzapine *v.* haloperidol in treatment. Pierre V. Tran *et al* 15–22

Schizophrenia
Aetiology
Lipids. Nicholas P. Walker *et al* (*Editorial*) 101–104
People at risk. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557
Complications
Anorexia nervosa as a phenotype of cognitive impairment. Y. Yamashita *et al* (C) 558
Diabetes mellitus. D. Mohan *et al* (C) 180–181
Serious sex offending against women by men. Relationship of illness and psychotic symptoms to offending. Alan D. Smith and Pamela J. Taylor 233–237
Tardive dyskinesia in patients during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30
Diagnosis
Definitions. M. B. First and H. A. Pincus (C) 273
Significance of Schneider's first-rank symptoms. Victor Peralta and Manuel J. Cuesta 243–248
Epidemiology
People at risk. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557
Focus on schizophrenia. G. D. Tollefson (ed.) (suppl. 37) 1–44
An approach to treatment resistance. Stephen R. Marder 19–22
Cholinergic aspects. Rajiv Tandon 7–11
CNS drug discovery in the 21st century. Steven Paul 23–25
Cognitive deficit and its neurochemical basis. Alan Breier 16–18
Glutamatergic aspects. Carol Tamminga 12–15
Glutamatergic deficiency model. A. Carlsson *et al* 2–6
Introduction. G. D. Tollefson 1
Olanzapine: a basic science update. Franklin Bymaster *et al* 36–40
Olanzapine in long-term treatment. John Kane 26–29
Olanzapine: preclinical pharmacology and recent findings. Nick A. Moore 41–44
Review of recent clinical studies with olanzapine. Gary D. Tollefson and Amy J. Kuntz 30–35
Genetics
Of novel therapeutic targets. R. Kerwin and M. Owen (suppl. 38) 1–4
People at risk. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Ann Hodges *et al* (*Preliminary report*) 547–553. Invited commentaries. Anne Farmer; Kenneth S. Kendler; Assen Jablensky; T. J. Crow; author's response by Eve Johnstone 554–557
Outcome
Cantabria First-Episode Schizophrenia Study: three-year follow-up. José L. Vázquez-Barquero *et al* 141–149
Pathology
Reduction of the parahippocampal gyrus and hippocampus. Kamran Razi *et al* 512–519
Pathophysiology
A disorder of the corollary discharge, feed forward systems of thought. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204
In vivo neuropharmacology. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33
Lipids. Nicholas P. Walker *et al* (*Editorial*) 101–104
Neurochemical alterations affecting putative receptor targets of atypical antipsychotics. P. J. Harrison (suppl. 38) 12–22
Paying attention to emotion. Stephan F. Taylor and Israel Liberzon (*Editorial*) 6–8
Psychology
Cognitive effects of conventional and atypical antipsychotics. Tonmoy Sharma (suppl. 38) 44–51
Coping strategies in relatives before and after psychiatric admission. Marcia Scazufca and Elizabeth Kuipers 154–158
Emotional functions and cognitive processes. D. M. Barbenel (C) 462. S. F. Taylor and I. Liberzon (*Authors' reply*) (C) 462–463
Family burden. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Paying attention to emotion. Stephan F. Taylor and Israel Liberzon (*Editorial*) 6–8
Therapy
Behavioural pharmacology of new antipsychotics. N. A. Moore (suppl. 38) 5–11
Cognitive effects of conventional and atypical antipsychotics. Tonmoy Sharma (suppl. 38) 44–51
Diabetes mellitus. D. Mohan *et al* (C) 180–181

Durability of effects of cognitive–behavioural therapy. Nicholas Tarrier *et al* 500–504
Genetics of novel therapeutic targets. R. Kerwin and M. Owen (suppl. 38) 1–4
In vivo neuropharmacology. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33
Needs-based psychosocial intervention service for carers. Christine Barrowclough *et al* 505–511
Neurochemical alterations affecting putative receptor targets of atypical antipsychotics. P. J. Harrison (suppl. 38) 12–22
Tardive dyskinesia in patients during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30
The difficult patient. Role of 'scientific psychiatry' in understanding patients with chronic schizophrenia or severe personality disorder. R. D. Hinshelwood (*Editorial*) 187–190

Schizotypal personality disorder
Aetiological risk factors for personality disorders. Jeremy W. Coid 530–538
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553

SCL–90–R
Continuing treatment of panic disorder after acute response: trial with fluoxetine. David Michelson *et al* 213–218

Scotland
Growth of insanity. Henry Rollin (*One hundred years ago*) 565–566
see also **Edinburgh High-Risk Study**

Selective serotonin reuptake inhibitors
Changes in personality traits with sertraline or citalopram. Lisa Ekselius and Lars von Knorring 444–448
see also **Fluoxetine**

Self-poisoning *see* **Deliberate self-harm**

Serotonin
Brain mechanisms associated with depressive relapse following acute tryptophan depletion. K. A. Smith *et al* 525–529

Serotonin receptors
CNS drug discovery in the 21st century. Steven Paul (suppl. 37) 23–25
Development of obsessive and depressive symptoms during risperidone treatment. B. Panagiotis *et al* (C) 559
Genetics of novel therapeutic targets in schizophrenia. R. Kerwin and M. Owen (suppl. 38) 1–4
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33
Olanzapine: a basic science update. Franklin Bymaster *et al* (suppl. 37) 36–40
Receptor alterations in schizophrenia. P. J. Harrison (suppl. 38) 12–22
Treatment of neuroleptic-induced akathisia with the 5-HT_2 antagonist mianserin. M. Poyurovsky *et al* 238–242

Sertraline
Or citalopram. Changes in personality traits during treatment. Lisa Ekselius and Lars von Knorring 444–448

Sex offenders
Aged and dangerous. Old age forensic psychiatry. Graeme Yorston (*Editorial*) 193–195
Serious offending against women by men with schizophrenia. Alan D. Smith and Pamela J. Taylor 233–237

Shyness
Childhood shyness and maternal social phobia. Peter J. Cooper and Marian Eke 439–443

Single photon emission tomography
In vivo neuropharmacology of schizophrenia. V. Bigliani and L. S. Pilowsky (suppl. 38) 23–33

Smoking
Efficacy of bupropion for cessation in smokers with a former history of major depression or alcoholism. K. E. Hayford *et al* 173–178

Social Behaviour Schedule
Validation of the HoNOS. Paul Bebbington *et al* 389–394

Social factors
Befriending for chronic depression among women in an inner city. II. Role of fresh-start experiences and baseline psychosocial factors in remission. Tirril Harris *et al* 225–232
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
Family burden of schizophrenia and depressive illness. Effects of ethnicity, gender and social ecology. Janis H. Jenkins and John G. Schumacher 31–38
Psychosocial adversity and child psychopathology. Michael L. Rutter (*Review Article*) 480–493

Social phobia
Childhood shyness and maternal social phobia. Peter J. Cooper and Marian Eke 439–443

Social Role Performance Schedule
Validation of the HoNOS. Paul Bebbington *et al* 389–394

Social support
Befriending for chronic depression among women in an inner city. I. & II. Tirril Harris *et al* 219–224, 225–232

Social workers
Cost-effectiveness of a home-based intervention for children and adolescents who have deliberately poisoned themselves. Sarah Byford *et al* 56–62

Special hospitals
Limits to the value of mental health review tribunals for offender patients. Pamela J. Taylor *et al* 164–169

Stalking
False claims of victimisation. Michele Pathé *et al* 170–172

Statistics *see* **Analyses**

Stigma
Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14
Of mental illness. Peter Byrne (*Editorial*) 1–2

Structured Clinical Interview for DSM–III–R
Impact of pregnancy on bulimia nervosa. John Farnill Morgan *et al* 135–140

Structured Inventory for Schizotypy
People at risk of schizophrenia. Ann Hodges *et al* (*Preliminary report*) 547–553

Substance misuse *see* **Alcohol** *and* **Drug misuse**

'Subthreshold' mental disorders
Review and synthesis of studies on minor depression and other 'brand names'. Harold Alan Pincus *et al* (*Review Article*) 288–296

Suicide
In farmers. R. A. Collacott (C) 369. K. Hawton (*Author's reply*) (C) 369
Psychotropics and prevention. Toxicological screening in Sweden 1992 to 1994. Göran Isacsson *et al* 259–265

Sweden
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265

Symptoms
Behavioural changes and psychiatric symptoms in Alzheimer's disease. Tony Hope *et al* 39–44. G. A. Jackson (C) 561–562. T. Hope (*Author's reply*) (C) 562
Cross-cultural comparison of depressive symptoms does not support stereotypes of ageing. J. R. M. Copeland *et al* (*EURODEP Study*) 322–329

Depression symptoms in late life assessed using the EURO–D scale. M. J. Prince *et al* (*EURODEP Study*) 339–345
Development of obsessive and depressive symptoms during risperidone treatment. B. Panagiotis *et al* (C) 559
Development of the EURO–D scale to compare symptoms of depression. M. J. Prince *et al* (*EURODEP Study*) 330–338
Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Victor Peralta and Manuel J. Cuesta 243–248
Neurobehavioural symptoms one year after head injury. Shoumitro Deb *et al* 360–365
Serious sex offending against women by men with schizophrenia. Relationship of illness and psychotic symptoms to offending. Alan D. Smith and Pamela J. Taylor 233–237

Tardive dyskinesia
Incidence in patients with schizophrenia during treatment with olanzapine or haloperidol. Charles M. Beasley *et al* 23–30
Olanzapine in long-term treatment of schizophrenia. John Kane (suppl. 37) 26–29
Side-effects and safety of new antipsychotics. Thomas R. E. Barnes and Mike A. McPhillips (suppl. 38) 34–43

Ten books
Robert Cawley 464–467

Terminology
Definitions of depression. P. Tharyan and G. Raghuthaman (C) 559–560
'Patient *v.* client'. A. D. Jager (C) 180

Tetrahydroaminoacridine (tacrine)
New drugs for Alzheimer's disease. Alistair Burns *et al* (*Editorial*) 476–479

Thought disorder
Emotional functions and cognitive processes. D. M. Barbenel (C) 462. S. F. Taylor and I. Liberzon (*Authors' reply*) (C) 462–463
Schizophrenia – a disorder of the corollary discharge, feed forward systems of thought. Irwin Feinberg and Mario Guazzelli (*Review Article*) 196–204

Toxicological screening
Orphenadrine. Lars Slørdal and Pål Gjerden (C) 275–276
Psychotropics and suicide prevention. Göran Isacsson *et al* 259–265

Transcranial magnetic stimulation
B. Moore (C) 273
Reduced cortical excitability in depression. Impaired post-exercise motor facilitation. P. M. Shajahan *et al* 449–454

Trauma
Sudden loss of hair due to mental shock. Henry Rollin (*One hundred years ago*) 80
see also **Post-traumatic stress disorder**

Traumatic grief
And PTSD. Criteria. G. C. Fox *et al* (C) 560. H. G. Prigerson *et al* (*Authors' reply*) (C) 560–561
Consensus criteria. H. G. Prigerson *et al* (*Preliminary report*) 67–73

Tryptophan
Brain mechanisms associated with depressive relapse following acute depletion. K. A. Smith *et al* 525–529

Unconsciousness
And PTSD. H. L. Freeman (C) 79
Traumatic brain injury and PTSD. T. McMillan and R. R. Jacobson (C) 274–275. D. Nutt (*Author's reply*) (C) 275

United Kingdom
Economic impact of Alzheimer's disease. E. Souêtre *et al* 51–55
see also **Britain**

Unreliable confessions
To homicide. Case of misdiagnosis of amnesia and misuse of abreaction technique. Gisli H. Gudjonsson *et al* 455–459

Urban populations
Befriending for chronic depression among women in an inner city. I. & II. Tirril Harris *et al* 219–224, 225–232
Fever and acute brief psychosis in north India. Pamela Y. Collins *et al* 520–524

Vascular disease
Detecting vascular pathology in vascular dementia. R. Rao (C) 562. C. Holmes and N. Cairns (*Authors' reply*) (C) 563
Hypertension and cognitive decline. Robert Stewart (*Editorial*) 286–287
Validity of current clinical criteria for dementias. Clive Holmes *et al* 45–50

Verona Service Satisfaction Scale
Satisfied with dissatisfaction? A. Key *et al* (C) 273–274

Victoria (Australia)
HoNOS. Results of the field trial. T. Trauer *et al* 380–388

Wales
And England. Homicides by people with mental illness: myth and reality. Pamela J. Taylor and John Gunn (*Review Article*) 9–14

Women
Befriending as an intervention for chronic depression in an inner city. Tirril Harris *et al*
I. Randomised controlled trial 219–224
II. Role of fresh-start experiences and baseline psychosocial factors in remission 225–232
Childhood shyness and maternal social phobia. Peter J. Cooper and Marian Eke 439–443
Early life family disadvantages and major depression in adulthood. H. Sadowski *et al* 112–120
Impact of pregnancy on bulimia nervosa. John Farnill Morgan *et al* 135–140
Review of community prevalence of depression in later life. A. T. F. Beekman *et al* (*EURODEP Study*) 307–311
see also **Gender differences**

PART II. CONTRIBUTORS

Abed, R. T. and **Cooper, M.** Mirtazepine causing hyperphagia (C) 181
Aevarsson, Ólafur *see* **Pálsson, Sigurdur** *et al* 249–253
Ambrose, A. and **Salib, E.** Amiodarone-induced depression (C) 366–367
Amin, S. *et al*. Evaluating the Health of the Nation Outcome Scales. Reliability and validity in a three-year follow-up of first-onset psychosis 399–403
Andrews, Gavin *et al*. Classification in psychiatry: ICD–10 *versus* DSM–IV (*Editorial*) 3–5
Aris, L. *see* **Panagiotis, B.** *et al* (C) 559

Barbenel, D. M. Emotional functions and cognitive processes (C) 462
Barel, Y. C. *see* **Katz, G.** *et al* (C) 558–559
Barker, A. *see* **Mohan, D.** *et al* (C) 180–181
Barnes, J. *see* **Sadowski, H.** *et al* 112–120
Barnes, Thomas R. E. and **McPhillips, Mike A.** Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics (suppl. 38) 34–43

Barrowclough, C. *see* **Haddock, G.** *et al* (C) 370

Barrowclough, Christine *et al*. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia 505–511

Beasley, Charles M. *et al*. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol 23–30

Beasley, Charles M., Jr *see* **Tran, Pierre V.** *et al* 15–22

Bebbington, Paul *et al*. Validation of the Health of the Nation Outcome Scales 389–394

Beck, Andrew *see* **Slade, Mike** *et al* 404–408

Beekman, A. T. F. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Beekman, A. T. F. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Beekman, A. T. F. *et al*. Review of community prevalence of depression in later life (*EURODEP Study*) 307–311

Beevor, A. *see* **Burns, A.** *et al* 424–427, 435–438

Beevor, A. *see* **Gowers, S. G.** *et al* 413–416, 428–431

Beevor, A. *see* **Wing, J.** *et al* 432–434

Benkert, O. *see* **Loerch, B.** *et al* 205–212

Berg, Paul H. *see* **Tran, Pierre V.** *et al* 15–22

Bergman, Ulf *see* **Isacsson, Göran** *et al* 259–265

Bigliani, V. and **Pilowsky, L. S.** *In vivo* neuropharmacology of schizophrenia (suppl. 38) 23–33

Bindman, Jonathan *see* **Slade, Mike** *et al* 404–408

Birmingham, Luke. Between prison and the community. The 'revolving door psychiatric patient' of the nineties (*Editorial*) 378–379

Blakey, A. *see* **Burns, A.** *et al* 424–427, 435–438

Blazer, Dan. EURODEP Consortium and late-life depression (*Editorial*) 284–285

Boardman, A. P. Effectiveness of community psychiatry (C) 179

Bollini, Paola *et al*. Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in randomised clinical trials (*Review Article*) 297–303

Bolt, J. *see* **Wilcock, M.** *et al* (C) 277

Bowden, P. *see* **Szmukler, G.** *et al* (C) 564–565

Bracken, P. *et al*. Mental health among Irish people living in Britain (*Authors' reply*) (C) 80

Brandes, Dalia *see* **Freedman, Sara A.** *et al* 353–359

Breier, Alan. Cognitive deficit in schizophrenia and its neurochemical basis (suppl. 37) 16–18

Brewin, John *see* **Cantwell, Roch** *et al* 150–153

Bristow, Mike *see* **Greenwood, Nan** *et al* 159–163

Brown, George W. *see* **Harris, Tirril** *et al* 219–224, 225–232

Brugha, Terry *see* **Bebbington, Paul** *et al* 389–394

Burns, A. *et al*. Health of the Nation Outcome Scales for Elderly People (HoNOS 65+) 424–427

Burns, A. *et al*. Health of the Nation Outcome Scales for Elderly People (HoNOS 65+). Glossary for HoNOS 65+ score sheet 435–438

Burns, Alistair *et al*. New drugs for Alzheimer's disease (*Editorial*) 476–479

Burns, T. *see* **Key, A.** *et al* (C) 273–274

Burns, Tom *see* **Greenwood, Nan** *et al* 159–163

Burns, Tom and **Priebe, Stefan.** Mental health care failure in England. Myth and reality (*Editorial*) 191–192

Butwell, Martin *see* **Taylor, Pamela J.** *et al* 164–169

Byford, Sarah *et al*. Cost-effectiveness analysis of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Results of a randomised controlled trial 56–62

Bymaster, Franklin *et al*. Olanzapine: a basic science update (suppl. 37) 36–40

Byrne, Majella *see* **Hodges, Ann** *et al* (*Preliminary report*) 547–553

Byrne, Peter. Stigma of mental illness. Changing minds, changing behaviour (*Editorial*) 1–2

Cairns, N. *see* **Holmes, C.** (*Authors' reply*) (C) 563

Cairns, Nigel *see* **Holmes, Clive** *et al* 45–50

Callaly, T. *see* **Trauer, T.** *et al* 380–388

Calligaro, David O. *see* **Bymaster, Franklin** *et al* (suppl. 37) 36–40

Cantwell, Roch *et al*. Prevalence of substance misuse in first-episode psychosis 150–153

Carlsson, A. *et al*. A glutamatergic deficiency model of schizophrenia (suppl. 37) 2–6

Carlsson, M. L. *see* **Carlsson, A.** *et al* (suppl. 37) 2–6

Castanedo, Sara Herrera *see* **Vázquez-Barquero, José L.** *et al* 141–149

Cawley, Robert. Ten books 464–467

Chakrabarti, S. and **Kulhara, P.** Family burden of caring for people with mental illness (C) 463

Checkley, S. A. *see* **Malhi, G. S.** (C) 460

Checkley, Stuart *see* **Sigurdsson, Engilbert** *et al* 121–127

Clark, D. M. and **Salkovskis, P. M.** Psychological treatments for hypochondriasis (*Authors' reply*) (C) 367–368

Coid, Jeremy W. Aetiological risk factors for personality disorders 530–538

Collacott, R. A. Shotguns and blunderbusses: suicide in farmers (C) 369

Collins, Pamela Y. *et al*. Fever and acute brief psychosis in urban and rural settings in north India 520–524

Cooper, M. *see* **Abed, R. T.** (C) 181

Cooper, Peter J. and **Eke, Marian.** Childhood shyness and maternal social phobia: a community study 439–443

Copeland, J. R. M. *see* **Beekman, A. T. F.** *et al* (*EURODEP Study*) 307–311

Copeland, J. R. M. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Copeland, J. R. M. Depression of older age. Origins of the study (*EURODEP Study*) 304–306

Copeland, J. R. M. *et al*. Cross-cultural comparison of depressive symptoms in Europe does not support stereotypes of ageing (*EURODEP Study*) 322–329

Copeland, J. R. M. *et al*. Depression in Europe. Geographical distribution among older people (*EURODEP Study*) 312–321

Cowen, P. J. *see* **Smith, K. A.** *et al* 525–529

Croghan, I. T. *see* **Hayford, K. E.** *et al* 173–178

Croudace, T. *see* **Amin, S.** *et al* 399–403

Crow, T. J. Invited commentary on: People at risk of schizophrenia 555–556

Cuesta, Manuel J. *see* **Peralta, Victor** 243–248

Cuesta, Maria J. *see* **Vázquez-Barquero, José L.** *et al* 141–149

Curtis, R. H. *see* **Wing, J.** *et al* 432–434

Dalkin, Tim *see* **Cantwell, Roch** *et al* 150–153

Davidson, J. R. T. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Davis, Wendy Wakefield *see* **Pincus, Harold Alan** *et al* (*Review Article*) 288–296

Day, Richard *see* Collins, Pamela Y. *et al* 520–524

Deb, Shoumitro *et al*. Neurobehavioural symptoms one year after a head injury 360–365

Deeg, D. J. H. *see* Prince, M. J. *et al* (*EURODEP Study*) 339–345

Deforge, Bruce *see* Lehman, Anthony F. *et al* 346–352

DeLisi, Lynn E. *see* Razi, Kamran *et al* 512–519

Dellva, Mary Anne *see* Beasley, Charles M. *et al* 23–30

deVries, M. W. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321

Dewey, M. E. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Dixon, Lisa *see* Lehman, Anthony F. *et al* 346–352

Dolan, R. J. *see* Smith, K. A. *et al* 525–529

Doyle, C. *see* Fox, G. C. *et al* (C) 560

Druid, Henrik *see* Isacsson, Göran *et al* 259–265

Dunn, Graham *see* Vázquez-Barquero, José L. *et al* 141–149

Dunn, Graham *et al*. Two-phase epidemiological surveys in psychiatric research (*Editorial*) 95–100

Durst, R. *see* Katz, G. *et al* (C) 558–559

Dyer, Elizabeth *see* Byford, Sarah *et al* 56–62

Ebmeier, K. P. *see* Shajahan, P. M. *et al* 449–454

Eke, Marian *see* Cooper, Peter J. 439–443

Ekselius, Lisa and von Knorring, Lars. Changes in personality traits during treatment with sertraline or citalopram 444–448

Fairburn, Christopher G. *see* Hope, Tony *et al* 39–44

Farmer, Anne. Invited commentary on: People at risk of schizophrenia 554

Farmer, Anne. The demise of the published case report – is resuscitation necessary? (*Editorial*) 93–94

Fear, Simon *see* Sharma, Vimal K. *et al* 395–398

Feinberg, Irwin and Guazzelli, Mario. Schizophrenia – a disorder of the corollary discharge systems that integrate the motor systems of thought with the sensory systems of consciousness (*Review Article*) 196–204

Ferguson, Kevin *see* Beasley, Charles M. *et al* 23–30

Fiander, M. *see* Key, A. *et al* (C) 273–274

Fichter, M. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 322–329

Fichter, M. *see* Prince, M. J. *et al* (*EURODEP Study*) 330–338

First, M. B. and Pincus, H. A. Definitions of schizophrenia (C) 273

Fluoxetine Panic Disorder Study Group *see* Michelson, David *et al* 213–218

Fombonne, E. *see* Sigurdsson, E. (*Authors' reply*) (C) 563–564

Fombonne, Eric *see* Sigurdsson, Engilbert *et al* 121–127

Fourie, H. *see* Jha, A. (C) 366

Fox, G. C. *et al*. Criteria for traumatic grief and PTSD (C) 560

Fox, Helen C. *see* Walker, Nicholas P. *et al* (*Editorial*) 101–104

Fox, Richard *see* Cantwell, Roch *et al* 150–153

Frank, E. *see* Prigerson, H. G. *et al* (*Preliminary report*) 67–73

Frank, Richard *see* Lehman, Anthony F. *et al* 346–352

Freedman, Sara A. *et al*. Predictors of chronic post-traumatic stress disorder. A prospective study 353–359

Freeman, H. L. Unconsciousness and PTSD (C) 79

Friston, K. J. *see* Smith, K. A. *et al* 525–529

Fuchs, C. *see* Poyurovsky, M. *et al* 238–242

Fuhrer, R. *see* Prince, M. J. *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Gangadhar, B. N. *see* Mayur, Prashanth M. *et al* 270–272

Garralda, M. E. *see* Yates, P. *et al* 417–423

Ge, Shuming *see* Razi, Kamran *et al* 512–519

Gill, Julia *see* Byford, Sarah *et al* 56–62

Gjerden, Pål *see* Slørdal, Lars (C) 275–276

Glabus, M. F. *see* Shajahan, P. M. *et al* 449–454

Glazebrook, Cristine *see* Cantwell, Roch *et al* 150–153

Glazer, William M. *see* Beasley, Charles M. *et al* 23–30

Glover, E. D. *see* Hayford, K. E. *et al* 173–178

Goldberg, Emma *see* Taylor, Pamela J. *et al* 164–169

Gooding, P. A. *see* Shajahan, P. M. *et al* 449–454

Gordon, H. *see* Mohan, D. *et al* (C) 180–181

Gosden, R. Early psychosis (C) 461

Gowers, S. G. *et al*. Brief scale for measuring the outcomes of emotional and behavioural disorders in children. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) 413–416

Gowers, S. G. *et al*. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Glossary for HoNOSCA score sheet 428–431

Gowers, Simon and North, Clive. Difficulties in family functioning and adolescent anorexia nervosa 63–66

Graf-Morgenstern, M. *see* Loerch, B. *et al* 205–212

Grant, Elizabeth *see* Hodges, Ann *et al* (*Preliminary report*) 547–553

Greene, Kimberly P. *see* Razi, Kamran *et al* 512–519

Greenslade, L. *see* Bracken, P. *et al* (*Authors' reply*) (C) 80

Greenwood, Nan *et al*. Satisfaction with in-patient psychiatric services. Relationship to patient and treatment factors 159–163

Griffin, B. *see* Bracken, P. *et al* (*Authors' reply*) (C) 80

Groves, P. Meditation and anxiety (C) 79

Guazzelli, Mario *see* Feinberg, Irwin (*Review Article*) 196–204

Gudjonsson, Gisli H. *et al*. Unreliable admissions to homicide. A case of misdiagnosis of amnesia and misuse of abreaction technique 455–459

Gunn, John *see* Taylor, Pamela J. (*Review Article*) 9–14

Hadden, S. *see* Burns, A. *et al* 424–427, 435–438

Haddock, G. *et al*. Hair analysis for substance use (C) 370

Hain, C. *see* Loerch, B. *et al* 205–212

Hamlin, Charlotte *see* Barrowclough, Christine *et al* 505–511

Handysides, Julia *see* Orrell, Martin *et al* 409–412

Hansson, L. O. *see* Carlsson, A. *et al* (suppl. 37) 2–6

Hantz, P. *see* Trauer, T. *et al* 380–388

Harrington, R. C. *see* Gowers, S. G. *et al* 413–416, 428–431

Harrington, Richard *see* Byford, Sarah *et al* 56–62

Harrington, Richard *see* Thapar, Anita *et al* (*Review Article*) 105–111

Harrington, Val *see* Byford, Sarah *et al* 56–62

Harris, Tirril *et al*. Befriending as an intervention for chronic depression among women in an inner city. I. Randomised controlled trial 219–224

Harris, Tirril *et al*. Befriending as an intervention for chronic depression among women in an inner city. II. Role of fresh-start experiences and baseline psychosocial factors in remission from depression 225–232

Harrison, G. *see* **Amin, S.** *et al* 399–403

Harrison, Glynn *see* **Cantwell, Roch** *et al* 150–153

Harrison, P. J. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D_1, D_3, D_4) and 5-HT_{2a} receptors (suppl. 38) 12–22

Hautzinger, M. *see* **Loerch, B.** *et al* 205–212

Hawton, K. Shotguns and blunderbusses: suicide in farmers (*Author's reply*) (C) 369

Hayford, K. E. *et al*. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism 173–178

Herrán, Andrés *see* **Vázquez-Barquero, José L.** *et al* 141–149

Higginson, I. *see* **Yates, P.** *et al* 417–423

Hill, Trevor *see* **Bebbington, Paul** *et al* 389–394

Hindley, N. *see* **Mohan, D.** *et al* (C) 180–181

Hinshelwood, R. D. The difficult patient. The role of 'scientific psychiatry' in understanding patients with chronic schizophrenia or severe personality disorder (*Editorial*) 187–190

Hoch, Jeffrey S. *see* **Lehman, Anthony F.** *et al* 346–352

Hodges, Ann *et al*. People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study (*Preliminary report*) 547–553

Holloway, F. *see* **Szmukler, G.** *et al* (C) 564–565

Holmes, C. and **Cairns, N.** Detecting vascular pathology in vascular dementia (*Authors' reply*) (C) 563

Holmes, Clive *et al*. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies 45–50

Holmes, Jane *see* **Thapar, Anita** *et al* (*Review Article*) 105–111

Holmgren, Per *see* **Isacsson, Göran** *et al* 259–265

Hooijer, C. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321

Hope, T. Behavioural changes and psychiatric symptoms in Alzheimer's disease (*Author's reply*) (C) 562

Hope, Tony *et al*. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study 39–44

Humphreys, Lloyd *see* **Tarrier, Nicholas** *et al* 500–504

Hurt, R. D. *see* **Hayford, K. E.** *et al* 173–178

Isacsson, Göran *et al*. Psychotropics and suicide prevention. Implications from toxicological screening of 5281 suicides in Sweden 1992 to 1994. 259–265

Jablensky, Assen. Invited commentary on: People at risk of schizophrenia 555

Jackson, G. A. Behavioural changes and psychiatric symptoms in Alzheimer's disease (C) 561–562

Jacobs, S. C. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73, (*Authors' reply*) (C) 560–561

Jacobson, R. R. *see* **McMillan, T.** (C) 274–275

Jacoby, Robin *see* **Hope, Tony** *et al* 39–44

Jager, A. D. 'Patient *v.* client' (C) 180

Janakiramaiah, N. *see* **Mayur, Prashanth M.** *et al* 270–272

Jenkins, Janis H. and **Schumacher, John G.** Family burden of schizophrenia and depressive illness. Specifying the effects of ethnicity, gender and social ecology 31–38

Jezzard, R. *see* **Gowers, S. G.** *et al* 413–416, 428–431

Jha, A. and **Fourie, H.** Risperidone treatment of amphetamine psychosis (C) 366

John, Jacob Kochukaleekal *see* **Russell, Paul Swamidhas Sudhakar** *et al* 254–258

Johnstone, Eve *see* **Hodges, Ann** *et al* (*Preliminary report*) 547–553

Johnstone, Eve. Invited commentaries on: People at risk of schizophrenia (*Author's reply*) 556–557

Jones, P. *see* **Amin, S.** *et al* 399–403

Jonker, C. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338

Jordan, A. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Joyce, A. S. *et al*. Developing theoretically relevant measures of psychoanalytic constructs (C) 179–180

Kane, John. Olanzapine in the long-term treatment of schizophrenia (suppl. 37) 26–29

Kaplan, C. *see* **Sadowski, H.** *et al* 112–120

Katz, G. *et al*. *De novo* jet-lag psychosis (C) 558–559

Kavanagh, Shane and **Knapp, Martin.** Cognitive disability and direct care costs for elderly people 539–546

Kawai, M. *see* **Yamashita, Y.** *et al* (C) 558

Keene, Janet *see* **Hope, Tony** *et al* 39–44

Kendler, Kenneth S. Invited commentary on: People at risk of schizophrenia 554–555

Kerfoot, Michael *see* **Byford, Sarah** *et al* 56–62

Kernan, Eimer *see* **Lehman, Anthony F.** *et al* 346–352

Kerwin, R. and **Owen, M.** Genetics of novel therapeutic targets in schizophrenia (suppl. 38) 1–4

Key, A. *et al*. Satisfied with dissatisfaction? (C) 273–274

Key, Adrienne *see* **Greenwood, Nan** *et al* 159–163

Kinney, Caroline *see* **Tarrier, Nicholas** *et al* 500–504

Kinsella, A. *see* **Waddington, J. L.** *et al* (*Authors' reply*) (C) 368–369

Kirby, M. Use of long-acting benzodiazepines in older people (C) 460–461

Kivela, S.-L. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Knapp, Martin *see* **Kavanagh, Shane** 539–546

Knobler, H. Y. *see* **Katz, G.** *et al* (C) 558–559

Kolvin, I. *see* **Sadowski, H.** *et al* 112–120

Kolvin, I. Talking with Michael Rutter (*Interview*) 494–499

Kolvin, I. The contribution of Michael Rutter (*Editorial*) 471–475

Kopelman, Michael D. *see* **Gudjonsson, Gisli H.** *et al* 455–459

Koutzoukis, Charis *see* **Deb, Shoumitro** *et al* 360–365

Kuipers, Elizabeth *see* **Scazufca, Marcia** 154–158

Kulhara, P. *see* **Chakrabarti, S.** (C) 463

Kuntz, Amy J. *see* **Tollefson, Gary D.** (suppl. 37) 30–35

Kupelnick, Bruce *see* **Bollini, Paola** *et al* (*Review Article*) 297–303

Kupfer, D. J. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Kushner, Maureen *see* **Razi, Kamran** *et al* 512–519

Lacey, J. Hubert *see* Morgan, John Farnill *et al* 135–140

Lakshmanan, Jeyaseelan L. *see* Russell, Paul Swamidhas Sudhakar *et al* 254–258

Lantos, Peter *see* Holmes, Clive *et al* 45–50

Lastra, Ismael *see* Vázquez-Barquero, José L. *et al* 141–149

Lawlor, B. A. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Lawlor, B. A. *see* Prince, M. J. *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Leese, Morven *see* Taylor, Pamela J. *et al* 164–169

Lehman, Anthony F. *et al*. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness 346–352

Lelliott, P. *see* Burns, A. *et al* 424–427, 435–438

Lelliott, P. *see* Gowers, S. G. *et al* 413–416, 428–431

Lewis, S. *see* Haddock, G. *et al* (C) 370

Lewis, Shôn *see* Barrowclough, Christine *et al* 505–511

Liberzon, I. *see* Taylor, S. F. (*Authors' reply*) (C) 462–463

Liberzon, Israel *see* Taylor, Stephan F. (*Editorial*) 6–8

Linden, M. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 322–329

Little, J. *see* Trauer, T. *et al* 380–388

Lobo, A. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Lobo, A. *see* Prince, M. J. *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Loerch, B. *et al*. Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia 205–212

Lu, Yili *see* Tran, Pierre V. *et al* 15–22

Lydiard, R. Bruce *see* Michelson, David *et al* 213–218

Lyons, Ita *see* Deb, Shoumitro *et al* 360–365

McCallum, M. *see* Joyce, A. S. *et al* (C) 179–180

McCarthy, Eilis *see* Tarrier, Nicholas *et al* 500–504

McConville, P. and Walker, N. Neurodevelopmental delay in the severely ill (C) 563

Macdonald, A. Orphenadrine – presence in patients not using antipsychotic drugs (C) 565

McGorry, P. Early psychosis (*Author's reply*) (C) 461–462

Maciejewski, P. K. *see* Prigerson, H. G. *et al* (*Preliminary report*) 67–73, (*Authors' reply*) (C) 560–561

MacKeith, James A. C. *see* Gudjonsson, Gisli H. *et al* 455–459

Mackenzie, I. *see* Wilcock, M. *et al* (C) 277

McKenzie, Nigel and Marks, Isaac. Quick rating of depressed mood in patients with anxiety disorders 266–269

Mckillop-Duffy, P. *see* Fox, G. C. *et al* (C) 560

McMillan, T. and Jacobson, R. R. Traumatic brain injury and post-traumatic stress disorder (C) 274–275

McNiven, Faye *see* Byford, Sarah *et al* 56–62

McPhillips, Mike A. *see* Barnes, Thomas R. E. (suppl. 38) 34–43

McQueen, Laurie E. *see* Pincus, Harold Alan *et al* (*Review Article*) 288–296

McShane, Rupert *see* Hope, Tony *et al* 39–44

Magnusson, H. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Magnusson, H. *see* Prince, M. J. *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Mainwaring, John *see* Barrowclough, Christine *et al* 505–511

Malhi, G. S. and Checkley, S. A. Olanzapine in the treatment of psychotic depression (C) 460

Mann, A. H. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Mann, Anthony *see* Holmes, Clive *et al* 45–50

Marder, Stephen R. An approach to treatment resistance in schizophrenia (suppl. 37) 19–22

Maria, G. *see* Panagiotis, B. *et al* (C) 559

Marks, I. Psychological treatments for hypochondriasis (C) 367

Marks, I. Satisfaction of carers at home (C) 369–370

Marks, Isaac *see* McKenzie, Nigel 266–269

Marsden, Lucy *see* Bebbington, Paul *et al* 389–394

Mayur, Prashanth M. *et al*. Motor seizure monitoring during electroconvulsive therapy 270–272

Medley, I. *see* Amin, S. *et al* 399–403

Medley, Ian *see* Cantwell, Roch *et al* 150–153

Mehta, Mitul A. *see* Ramana, Rajini *et al* 128–134

Meller, I. *see* Copeland, J. R. M. *et al* (*EURODEP Study*) 312–321

Meller, I. *see* Prince, M. J. *et al* (*EURODEP Study*) 339–345

Melzer, David *see* Ramana, Rajini *et al* 128–134

Michelson, David *et al*. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine 213–218

Mohan, D. *et al*. Schizophrenia and diabetes mellitus (C) 180–181

Mojtabai, Ramin *see* Collins, Pamela Y. *et al* 520–524

Moore, B. Transcranial magnetic stimulation (C) 273

Moore, N. A. Behavioural pharmacology of the new generation of antipsychotic agents (suppl. 38) 5–11

Moore, Nick A. *see* Bymaster, Franklin *et al* (suppl. 37) 36–40

Moore, Nick A. Olanzapine: preclinical pharmacology and recent findings (suppl. 37) 41–44

Morgan, John Farnill *et al*. Impact of pregnancy on bulimia nervosa 135–140

Morgenstern, Hal *see* Beasley, Charles M. *et al* 23–30

Mori, N. *see* Yamashita, Y. *et al* (C) 558

Morris, J. S. *see* Smith, K. A. *et al* 525–529

Morris, Julie *see* Tarrier, Nicholas *et al* 500–504

Mulinga, J. *see* Burns, A. *et al* 424–427, 435–438

Mullen, Paul E. *see* Pathé, Michele *et al* 170–172

Munizza, Carmine *see* Bollini, Paola *et al* (*Review Article*) 297–303

Nelson, David L. *see* Bymaster, Franklin *et al* (suppl. 37) 36–40

North, Clive *see* Gowers, Simon 63–66

Nutt, D. Traumatic brain injury and post-traumatic stress disorder (*Author's reply*) (C) 275

Offord, K. P. *see* Hayford, K. E. *et al* 173–178

O'Kelly, J. G. *see* Joyce, A. S. *et al* (C) 179–180

Orrell, M. *see* Burns, A. *et al* 424–427, 435–438

Orrell, Martin *et al*. Validity and reliability of the Health of the Nation Outcome Scales in psychiatric patients in the community 409–412

Owen, M. *see* Kerwin, R. (suppl. 38) 1–4

Oyen, H. van *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Page, Sean *see* **Burns, Alistair** *et al* (*Editorial*) 476–479

Pálsson, Sigurdur *et al*. Depression, cerebral atrophy, cognitive performance and incidence of dementia. Population study of 85-year-olds 249–253

Pampallona, Sandro *see* **Bollini, Paola** *et al* (*Review Article*) 297–303

Panagiotis, B. *et al*. Development of obsessive and depressive symptoms during risperidone treatment (C) 559

Pathé, Michele *et al*. Stalking: false claims of victimisation 170–172

Patten, C. A. *see* **Hayford, K. E.** *et al* 173–178

Paul, Steven. CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back (suppl. 37) 23–25

Paykel, Eugene S. *see* **Ramana, Rajini** *et al* 128–134

Peralta, Victor and **Cuesta, Manuel J.** Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders 243–248

Peri, Tuvia *see* **Freedman, Sara A.** *et al* 353–359

Perry, Kenneth W. *see* **Bymaster, Franklin** *et al* (suppl. 37) 36–40

Peters, Lorna *see* **Andrews, Gavin** *et al* (*Editorial*) 3–5

Pickles, Andrew *see* **Dunn, Graham** *et al* (*Editorial*) 95–100

Pilkonis, P. A. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Pilowsky, L. S. *see* **Bigliani, V.** (suppl. 38) 23–33

Pilowsky, L. S. *see* **Stephenson, C. M. E.** (suppl. 38) 52–58

Pincus, H. A. *see* **First, M. B.** (C) 273

Pincus, Harold Alan *et al*. 'Subthreshold' mental disorders. A review and synthesis of studies on minor depression and other 'brand names' (*Review Article*) 288–296

Piper, W. E. *see* **Joyce, A. S.** *et al* (C) 179–180

Plunkett, S. *see* **Purandare, N.** (C) 460

Pollack, Mark *see* **Michelson, David** *et al* 213–218

Poulton, Kay *see* **Thapar, Anita** *et al* (*Review Article*) 105–111

Poyurovsky, M. *et al*. Treatment of neuroleptic-induced akathisia with the 5-HT_2 antagonist mianserin. Double-blind, placebo-controlled study 238–242

Pradhan, S. C. and **Singh, M. Meghachandra.** The beginning and end of psychiatric pathways (C) 276

Priebe, Stefan *see* **Burns, Tom** (*Editorial*) 191–192

Prigerson, H. G. *et al*. Consensus criteria for traumatic grief. A preliminary empirical test (*Preliminary report*) 67–73

Prigerson, H. G. *et al*. Criteria for traumatic grief and PTSD (*Authors' reply*) (C) 560–561

Prince, M. J. *see* **Beekman, A. T. F.** *et al* (*EURODEP Study*) 307–311

Prince, M. J. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Prince, M. J. *et al*. Depression symptoms in late life assessed using the EURO–D scale. Effect of age, gender and marital status in 14 European Centres (*EURODEP Study*) 339–345

Prince, M. J. *et al*. Development of the EURO–D scale – a European Union initiative to compare symptoms of depression in 14 European centres (*EURODEP Study*) 330–338

Purandare, N. and **Plunkett, S.** Co-occurrence of polydactyly and psychosis (C) 460

Purcell, Rosemary *see* **Pathé, Michele** *et al* 170–172

Quinn, Joanne *see* **Barrowclough, Christine** *et al* 505–511

Raghuthaman, G. *see* **Tharyan, P.** (C) 559–560

Ramana, Rajini *et al*. Medication received by patients with depression following the acute episode: adequacy and relation to outcome 128–134

Rao, R. Detecting vascular pathology in vascular dementia (C) 562

Rasmussen, Kurt *see* **Bymaster, Franklin** *et al* (suppl. 37) 36–40

Razi, Kamran *et al*. Reduction of the parahippocampal gyrus and the hippocampus in patients with chronic schizophrenia 512–519

Reed, Alison *see* **Taylor, Pamela J.** *et al* 164–169

Reid, G. E. *see* **Fox, G. C.** *et al* (C) 560

Reischies, F. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321

Reischies, F. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Reynolds, C. F., III *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Robinson, Ruth *see* **Harris, Tirril** *et al* 219–224, 225–232

Roelands, M. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Rollin, Henry. From: medico-legal notes (*One hundred years ago*) 463

Rollin, Henry. Lunatics at large and the public press (*One hundred years ago*) 370

Rollin, Henry. States of over-excitability, hyper-sensitiveness, and mental explosiveness in children (*One hundred years ago*) 277

Rollin, Henry. Sudden loss of hair due to mental shock (*One hundred years ago*) 80

Rollin, Henry. "The growth of insanity in Scotland" (*One hundred years ago*) 565–566

Rollin, Henry. The Medico-Psychological Association of Britain and Ireland (*One hundred years ago*) 181–182

Rollin, Henry R. The *History of Lunacy* and the scholarship of Edward H. Hare (*Editorial*) 283

Rosenheck, R. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73, (*Authors' reply*) (C) 560–561

Rosie, J. S. *see* **Joyce, A. S.** *et al* (C) 179–180

Rummans, T. A. *see* **Hayford, K. E.** *et al* 173–178

Russell, Eve *see* **Burns, Alistair** *et al* (*Editorial*) 476–479

Russell, Paul Swamidhas Sudhakar *et al*. Family intervention for intellectually disabled children. Randomised controlled trial 254–258

Rutter, Michael L. Psychosocial adversity and child psychopathology (*Review Article*) 480–493

Sachs, D. P. L. *see* **Hayford, K. E.** *et al* 173–178

Sadowski, H. *et al*. Early life family disadvantages and major depression in adulthood 112–120

Sakuma, Michael *see* **Razi, Kamran** *et al* 512–519

Salib, E. *see* **Ambrose, A.** (C) 366–367

Salkovskis, P. M. *see* **Clark, D. M.** (*Authors' reply*) (C) 367–368

Salmon, A. *see* **Fox, G. C.** *et al* (C) 560

Sandmann, J. *see* **Loerch, B.** *et al* 205–212

Sanger, Todd M. *see* **Tran, Pierre V.** *et al* 15–22

Sayal, Kapil *see* **Sigurdsson, Engilbert** *et al* 121–127

Saz, P. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 322–329

Scazufca, Marcia and **Kuipers, Elizabeth**. Coping strategies in relatives of people with schizophrenia before and after psychiatric admission 154–158

Schapira, Robert *see* **Orrell, Martin** *et al* 409–412

Schlegel, S. *see* **Loerch, B.** *et al* 205–212

Schneidman, M. *see* **Poyurovsky, M.** *et al* 238–242

Schroeder, D. R. *see* **Hayford, K. E.** *et al* 173–178

Schumacher, John G. *see* **Jenkins, Janis H.** 31–38

Sedgwick, Philip *see* **Greenwood, Nan** *et al* 159–163

Sedgwick, Philip M. *see* **Morgan, John Farnill** *et al* 135–140

Sellwood, William *see* **Barrowclough, Christine** *et al* 505–511

Shah, P. J. *see* **Shajahan, P. M.** *et al* 449–454

Shajahan, P. M. *et al*. Reduced cortical excitability in depression. Impaired post-exercise motor facilitation with transcranial magnetic stimulation 449–454

Shalev, Arieh *see* **Freedman, Sara A.** *et al* 353–359

Shardorodsky, M. *see* **Poyurovsky, M.** *et al* 238–242

Sharma, Tonmoy. Cognitive effects of conventional and atypical antipsychotics in schizophrenia (suppl. 38) 44–51

Sharma, Vimal K. *et al*. Health of the Nation Outcome Scales: a case study in general psychiatry 395–398

Shear, M. K. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Shields, R. *see* **Trauer, T.** *et al* 380–388

Shih, D. *see* **Joyce, A. S.** *et al* (C) 179–180

Shiwach, R. S. Importance of case reports in psychiatry (C) 565

Sigurdsson, E. and **Fombonne, E.** Neurodevelopmental delay in the severely ill (*Authors' reply*) (C) 563–564

Sigurdsson, Engilbert *et al*. Neurodevelopmental antecedents of early-onset bipolar affective disorder 121–127

Singh, M. Meghachandra *see* **Pradhan, S. C.** (C) 276

Singh, S. P. *see* **Amin, S.** *et al* 399–403

Skoog, I. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Skoog, Ingmar *see* **Pálsson, Sigurdur** *et al* 249–253

Slade, Mike *et al*. Routine clinical outcome measures for patients with severe mental illness: CANSAS and HoNOS 404–408

Slade, Tim *see* **Andrews, Gavin** *et al* (*Editorial*) 3–5

Slørdal, Lars and **Gjerden, Pål**. Orphenadrine (C) 275–276

Smith, Alan D. and **Taylor, Pamela J.** Serious sex offending against women by men with schizophrenia. Relationship of illness and psychotic symptoms to offending 233–237

Smith, J. *see* **Trauer, T.** *et al* 380–388

Smith, K. A. *et al*. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion 525–529

Smyth, M. *see* **Bracken, P.** *et al* (*Authors' reply*) (C) 80

Snaith, R. P. Antipsychotic polypharmacy and early death (C) 368

Souêtre, E. *et al*. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease 51–55

Stein, G. S. Usefulness of the Health of the Nation Outcome Scales (*Editorial*) 375–377

Stephenson, C. M. E. and **Pilowsky, L. S.** Psychopharmacology of olanzapine. A review (suppl. 38) 52–58

Stewart, Robert. Hypertension and cognitive decline (*Editorial*) 286–287

Subbakrishna, D. K. *see* **Mayur, Prashanth M.** *et al* 270–272

Surtees, Paul G. *see* **Ramana, Rajini** *et al* 128–134

Susser, Ezra *see* **Collins, Pamela Y.** *et al* 520–524

Szmukler, G. *et al*. Homicides and community care: the evidence (C) 564–565

Takei, N. *see* **Yamashita, Y.** *et al* (C) 558

Tamminga, Carol. Glutamatergic aspects of schizophrenia (suppl. 37) 12–15

Tamura, Roy *see* **Michelson, David** *et al* 213–218

Tamura, Roy N. *see* **Beasley, Charles M.** *et al* 23–30

Tandon, Rajiv. Cholinergic aspects of schizophrenia (suppl. 37) 7–11

Tansella, Michele *see* **Dunn, Graham** *et al* (*Editorial*) 95–100

Tarrier, N. *see* **Haddock, G.** *et al* (C) 370

Tarrier, Nicholas *see* **Barrowclough, Christine** *et al* 505–511

Tarrier, Nicholas *et al*. Durability of the effects of cognitive–behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up 500–504

Taylor, J. Clinical outcome measurement (C) 179

Taylor, Pamela J. *see* **Smith, Alan D.** 233–237

Taylor, Pamela J. *et al*. Limits to the value of mental health review tribunals for offender patients. Suggestions for reform 164–169

Taylor, Pamela J. and **Gunn, John**. Homicides by people with mental illness: myth and reality (*Review Article*) 9–14

Taylor, S. F. and **Liberzon, I.** Emotional functions and cognitive processes (*Authors' reply*) (C) 462–463

Taylor, Stephan F. and **Liberzon, Israel**. Paying attention to emotion in schizophrenia (*Editorial*) 6–8

Tepner, Rosalinda *see* **Michelson, David** *et al* 213–218

Thapar, Anita *et al*. Genetic basis of attention deficit and hyperactivity (*Review Article*) 105–111

Tharyan, P. and **Raghuthaman, G.** Definitions of depression (C) 559–560

Thornicroft, G. *see* **Szmukler, G.** *et al* (C) 564–565

Thornicroft, Graham *see* **Slade, Mike** *et al* 404–408

Thwaites, R. M. A. *see* **Souêtre, E.** *et al* 51–55

Tibaldi, Giuseppe *see* **Bollini, Paola** *et al* (*Review Article*) 297–303

Tollefson, G. D. Introduction (suppl. 37) 1

Tollefson, Gary *see* **Michelson, David** *et al* 213–218

Tollefson, Gary D. *see* **Beasley, Charles M.** *et al* 23–30

Tollefson, Gary D. *see* **Tran, Pierre V.** *et al* 15–22

Tollefson, Gary D. and **Kuntz, Amy J.** Review of recent clinical studies with olanzapine (suppl. 37) 30–35

Torgerson, David *see* **Byford, Sarah** *et al* 56–62

Tran, Pierre V. *et al*. Olanzapine *versus* haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy 15–22

Trauer, T. *et al*. Health of the Nation Outcome Scales. Results of the Victorian field trial 380–388

Tringer, László. Focus on psychiatry in Hungary 81–85

Turrina, C. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Turrina, C. *see* **Prince, M. J.** *et al* (*EURODEP Study*) 330–338, (*EURODEP Study*) 339–345

Ugarte, B. *see* **Sadowski, H.** *et al* 112–120

UK700 Group. Comparison of intensive and standard case management for patients with psychosis. Rationale of the trial 74–78

Varma, Vijoy K. *see* **Collins, Pamela Y.** *et al* 520–524

Vázquez-Barquero, José L. *et al.* Cantabria First-Episode Schizophrenia Study: three-year follow-up 141–149

Vázquez-Barquero, José Luis *see* **Dunn, Graham** *et al* (*Editorial*) 95–100

von Knorring, Lars *see* **Ekselius, Lisa** 444–448

Waddington, J. L. *et al.* Antipsychotic polypharmacy and early death (*Authors' reply*) (C) 368–369

Walker, N. *see* **McConville, P.** (C) 563

Walker, Nicholas P. *et al.* Lipids and schizophrenia (*Editorial*) 101–104

Walsh, D. Mental health among Irish people living in Britain (C) 79–80

Waters, N. *see* **Carlsson, A.** *et al* (suppl. 37) 2–6

Weizman, A. *see* **Poyurovsky, M.** *et al* 238–242

Whalley, Lawrence J. *see* **Walker, Nicholas P.** *et al* (*Editorial*) 101–104

Whitton, A. *see* **Gowers, S. G.** *et al* 413–416, 428–431

Widiger, T. A. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Wig, Narendra N. *see* **Collins, Pamela Y.** *et al* 520–524

Wilcock, M. *et al.* County-wide survey of the repeat prescription of hypnotics (C) 277

Wilkinson, Greg *see* **Sharma, Vimal K.** *et al* 395–398

Williams, J. B. W. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Wilson, K. C. M. *see* **Copeland, J. R. M.** *et al* (*EURODEP Study*) 312–321, (*EURODEP Study*) 322–329

Window, Suzanne *see* **Bebbington, Paul** *et al* 389–394

Wing, J. *see* **Burns, A.** *et al* 424–427, 435–438

Wing, J. *see* **Gowers, S. G.** *et al* 413-416

Wing, J. *et al.* Health of the Nation Outcome Scales (HoNOS). Glossary for HoNOS score sheet 432–434

Wing, J. K. *see* **Gowers, S. G.** *et al* 428–431

Wittkowski, Anja *see* **Tarrier, Nicholas** *et al* 500–504

Wong, David T. *see* **Bymaster, Franklin** *et al* (suppl. 37) 36–40

Woodham, Adrine *see* **Byford, Sarah** *et al* 56–62

Wortman, C. B. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

Wright, Steve *see* **Slade, Mike** *et al* 404–408

Yamashita, Y. *et al.* Anorexia nervosa as a phenotype of cognitive impairment in schizophrenia (C) 558

Yard, Paula *see* **Orrell, Martin** *et al* 409–412

Yates, P. *et al.* Paddington Complexity Scale and Health of the Nation Outcome Scales for Children and Adolescents 417–423

Yeardley, H. L. *see* **Souêtre, E.** *et al* 51–55

Yorston, Graeme. Aged and dangerous. Old age forensic psychiatry (*Editorial*) 193–195

Youssef, H. A. *see* **Waddington, J. L.** *et al* (*Authors' reply*) (C) 368–369

Zisook, S. *see* **Prigerson, H. G.** *et al* (*Preliminary report*) 67–73

PART III. BOOK REVIEWS

Alarcon, R. D., Foulks, E. and **Vakkur, M.** Personality disorders and culture: clinical and conceptual interactions (Roland Littlewood) 279–280

Barker, P. and **Davidson, B.** (eds). Psychiatric nursing: ethical strife (Kevin Gournay) 88–89

Bear, Z. Good practice in counselling people who have been abused (Eileen Vizard) 373

Beaumont, B. and **Williams, C.** (eds). Care of drug users in general practice: a harm minimisation approach (S. M. Ruben) 89

Bendelow, Gillian and **Williams, Simon J.** (eds). Emotions in social life: critical themes and contemporary issues (D. W. Millard) 183–184

Brown, Thomas Markham and **Stoudemere, Alan.** Psychiatric side-effects of prescription and over-the-counter medications – recognition and management (David Taylor) 88

Decalmer, Peter and **Glendenning, Frank** (eds). The mistreatment of elderly people (2nd edn) (D. J. Jolley) 86

Dwivedi, Kedar Nath (ed.) The therapeutic use of stories (Andrew Clark) 90

Evans, John. Active analytic group therapy for adolescents (Roberta Mondadori and Tony Kaplan) 372–373

Foa, Edna B. and **Rothbaum, Barbara Olasov.** Treating the trauma of rape: cognitive–behavioral therapy for PTSD (Geraldine O'Sullivan) 88

Freeman, H., Pullen, I., Stein, G. and **Wilkinson, G.** (eds). Seminars in psychosexual disorders (Simon Dupont) 567

Fullerton, Carol S. and **Ursano, Robert J.** (eds). Post-traumatic stress disorder: acute and long-term responses to trauma and disaster (Stuart Turner) 87–88

Horowitz, Mardi Jon. Stress response syndromes: PTSD, grief and adjustment disorders (3rd edn) (Charles Montgomery) 87

Kadis, Leslie B. and **McClendon, Ruth.** Concise guide to marital and family therapy (Jessica Yakeley) 372

Kertesz, Andrew and **Munoz, David G.** (eds). Pick's disease and Pick complex (E. Jane Byrne) 86

Markovitz, John C. Interpersonal psychotherapy (L. Mynors-Wallis) 183

Matthews, Gerald and **Deary, Ian J.** Personality traits (Peter Tyrer) 89–90

Mollon, Phil. Remembering trauma: a psychotherapist's guide to memory and illusion (John Birchnell) 279

Patel, Vikram. Culture and common mental disorders in sub-Saharan Africa. Maudsley Monograph 41 (Ilona Blue) 90

Perry, P. J., Alexander, B. and **Liskov, B. I.** (eds). Psychotropic handbook (7th edn) (Stephen Curran) 371

Reite, Martin, Buddy, John and **Nagel, Kim.** Concise guide to evaluation and management of sleep disorders (2nd edn) (Peter B. C. Fenwick) 280

Ron, Maria A. and **David, Anthony S.** (eds). Disorders of brain and mind (Stephen M. Lawrie) 567

Schatzberg, A. F. and **Nemeroff, C. B.** Textbook of psychopharmacology (2nd edn) (David J. King) 371

Stewart, Danna E. and **Robinson, Gail** (eds). A clinician's guide to the menopause (Angelika Wieck) 86–87

Tantam, Digby (ed.). Clinical topics in psychotherapy (Frank Margison) 183

Wilkinson, Ian. Child and family assessment: clinical guidelines for practitioners (2nd edn) (Susan Bailey) 371–372

Yudofsky, S. and **Hales, R.** (eds). The American Psychiatric Press textbook of neuropsychiatry (3rd edn) (Guy Goodwin) 279